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Abstract 
Breast cancer, the most common malignancy diagnosed in women, is one of the leading 
causes of death in women worldwide. In South Africa only 32% of women diagnosed with 
advanced breast cancer survive more than five years. The search for new chemotherapeutic 
agents capable of effectively treating breast cancer is therefore essential. Recent evidence 
supporting the cancer stem cell theory of cancer development for breast cancer challenges the 
current theories of cancer development and hence treatment. Cancer stem cells are a small 
subpopulation of tumour cells that possess properties of both cancer cells and stem cells and 
are believed to be the tumour-initiating population of many cancers. Cancer stem cells are 
inherently resistant to many chemotherapeutic agents and in this way have been associated 
with repopulation of tumours after chemotherapy. This phenomenon is proposed as a possible 
mechanism for cancer relapse after treatment. Cancer stem cells have also been implicated in 
metastasis, the major cause of mortality in cancer patients. Therefore, any treatment that is 
capable of targeting and removing breast cancer stem cells may have the theoretical potential 
to effectively treat breast cancer. However, there are currently no such treatments available 
for clinical use. We were provided access to a library of novel indigenous small molecules 
isolated from red and brown algae found off the Eastern Cape of South Africa. The aim of this 
project was to analyse the anti-cancer and anti-cancer stem cell properties of the compounds 
in this library and to identify „hit‟ compounds which could form the basis for future 
development into new anti-cancer drugs. Ten novel compounds of algal origin were tested for 
cytotoxicity, by determining their ability to inhibit the growth of MCF12A breast epithelial 
cells and MCF7 breast cancer cells using the colorimetric MTT [(3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] cell proliferation assay. All but one of the compounds 
tested exhibited cytotoxicity towards the MCF7 cancer cell line, with IC50 values (the 
concentration of the compound that leads to a 50% inhibition in cell growth) of between 3 µM 
and 90 µM. The chemotherapeutic drug paclitaxel was used as a positive control. Four of the 
compounds (RUMB-001, RUMB-002, RUMB-007 and RUMB-010/saragaquinoic acid) were 
significantly more toxic to the MCF7 cancer cell line, than the „normal‟ MCF12A breast cells 
and were selected as priority compounds for further analyses. In addition, two other 
compounds were selected as priority compounds, one highly cytotoxic towards both MCF12A 
and MCF7 cell lines (RUMB-015) and one which was non toxic to either cell line (RUMB-
017/018). Preliminary studies into the mechanism of cytotoxicity using Western blot analysis 
for poly (ADP-ribose) polymerase (PARP) cleavage and Hoechst 33342 immunostaining in 
MCF-7 cells were largely unsuccessful. The Hoechst 33342 immunostaining assay did 
provide tentative evidence that selected priority compounds were capable of inducing 
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apoptosis, although these assays will need to be repeated using a less subjective assay to 
confirm the results. The priority compounds were subsequently investigated for their 
cytotoxic effect on the cancer stem cell-enriched side population in MCF7 cells. The ability of 
the priority compounds to selectively target the cancer stem cell containing side population 
was assessed using two complementary flow cytometry-based techniques – namely the 
Hoechst 33342-exclusion assay, and fluorescent immunostaining for the expression of the 
putative cancer stem cell marker, ABCG2+.  The ABCG2+ staining assay was a novel 
technique developed during the course of this study. It remains to be fully validated, but it 
may provide a new and reliable way to identify and analyse cancer stem cell containing side 
population cells. The MCF7 cells were treated with the compounds and the proportion of 
putative cancer stem cells compared with the size of the population in untreated cells was 
assessed. Three compounds (RUMB-010, RUMB-015 and RUMB-017/018) capable of 
reducing the proportion of side population cells within the MCF7 cell line were identified. 
Taking these data together, we identified two potential „hit‟ compounds which should be 
prioritised for future research. These are compounds RUMB-010/sargaquinoic acid and 
RUMB-017/018. RUMB-010 is of interest as it was shown to target the putative cancer stem 
cell population, in addition to the bulk MCF7 tumour line, but was relatively less toxic to the 
„normal‟ MCF12A cell line. RUMB-017/018 is of interest due to the ability to selectively 
target the cancer stem cell enriched side population, while having little effect on the normal 
(MCF12A) or bulk tumour (MCF7) cell lines tested. These compounds will be important as 
„hit‟ compounds for drug development and as tool compounds to study cancer and cancer 
stem cell biology.  
 
Jessica C Lawson 2010 
4 
 
Table of Contents 
 
ABSTRACT ................................................................................................................. 2 
TABLE OF CONTENTS .............................................................................................. 4 
LIST OF FIGURES ...................................................................................................... 7 
LIST OF TABLES ....................................................................................................... 8 
ACKNOWLEDGEMENTS ........................................................................................... 9 
OUTPUTS ................................................................................................................. 10 
AUTHOR’S DECLARATION ..................................................................................... 11 
ABBREVIATIONS ..................................................................................................... 12 
1 LITERATURE REVIEW ....................................................................................... 14 
1.1 Cancer ..............................................................................................................................................15 
1.2 Cancer Development ........................................................................................................................15 
1.3 Breast Cancer ..................................................................................................................................16 
1.3.1 Breast cancer subtypes ................................................................................................................16 
1.4 Theories of cancer development ......................................................................................................17 
1.4.1 Breast Cancer Development and Progression ...............................................................................17 
1.4.1.1 STOCHASTIC MODEL OF CANCER DEVELOPMENT AND SPORADIC AND 
FAMILIAL BREAST CANCER ........................................................................................................17 
1.4.1.2 CANCER STEM CELL THEORY OF CANCER DEVELOPMENT AND BREAST 
CANCER STEM CELLS ...................................................................................................................19 
1.5 Breast CSC and metastasis ..............................................................................................................23 
1.6 Current Breast Cancer Treatments and Limitations ......................................................................26 
1.7 Problem Statement and Knowledge Gap.........................................................................................31 
1.8 Hypothesis ........................................................................................................................................32 
1.9 Objectives .........................................................................................................................................32 
2 MATERIALS AND METHODS ............................................................................ 33 
2.1 Novel Indigenous Algal Compounds Isolated from Indigenous Red and Brown Algae .................34 
2.2 Cell Culture ......................................................................................................................................34 
2.3 Cytotoxicity Assays ..........................................................................................................................36 
Jessica C Lawson 2010 
5 
 
2.4 Putative cancer stem cell /Side Population Analyses .......................................................................37 
2.4.1 Flow Cytometry Based on Exclusion of Hoechst 33342 ...............................................................37 
2.4.2 Flow Cytometry Based on ABCG2 Staining ................................................................................38 
2.5 Apoptosis Assays ..............................................................................................................................39 
2.5.1 PARP detection using Western blot analysis ................................................................................39 
2.5.2 Immunofluorescent detection of apoptosis ...................................................................................39 
3 DETERMINATION OF CYTOTOXICITY OF MARINE COMPOUNDS IN MCF12A 
AND MCF7 CELLS ................................................................................................... 41 
3.1 Introduction .....................................................................................................................................42 
3.2 Results and Discussion .....................................................................................................................43 
3.2.1 Optimisation and validation of MTT assay on MCF12A and MCF7 cells using Paclitaxel ............44 
3.2.2 Determination of the IC50 values of algal compounds in MCF12A and MCF7 cells ......................45 
3.2.2.1 RUMB-001 ...................................................................................................................46 
3.2.2.2 RUMB-002 ...................................................................................................................47 
3.2.2.3 RUMB-003 ...................................................................................................................47 
3.2.2.4 RUMB-004 ...................................................................................................................48 
3.2.2.5 RUMB-005 ...................................................................................................................48 
3.2.2.6 RUMB-007 ...................................................................................................................48 
3.2.2.7 RUMB-008 ...................................................................................................................49 
3.2.2.8 RUMB-010 ...................................................................................................................49 
3.2.2.9 RUMB-015 ...................................................................................................................50 
3.2.2.10 RUMB-017/018 ............................................................................................................50 
3.3 Comparison of toxicity in normal and cancer cell lines ..................................................................64 
3.4 Conclusion ........................................................................................................................................69 
4 DETERMINATION OF THE CYTOTOXICITY OF THE PRIORITY COMPOUNDS 
ON THE SIDE POPULATION (SP) IN THE MCF7 BREAST CANCER CELL LINE 71 
4.1 Introduction .....................................................................................................................................72 
4.2 Results and Discussion .....................................................................................................................75 
4.2.1 Identification of the Side Population in MCF7 cell line using Hoechst staining.............................75 
4.2.2 Analysis of the percentage of ABCG2+ cells present in MCF7 cells after treatment with the priority 
compounds using flow cytometry ..............................................................................................................79 
4.3 Conclusion ........................................................................................................................................82 
5 DETERMINATION OF THE APOPTOTIC-INDUCING ABILITY OF THE 
PRIORITY COMPOUNDS ......................................................................................... 84 
5.1 Introduction .....................................................................................................................................85 
5.2 Results and Discussion .....................................................................................................................87 
5.2.1 Detection of PARP in MCF7 cells after treatment with the priority compounds ............................87 
5.2.2 Detection of apoptosis in MCF7 cells after treatment with the priority compounds using Hoechst 
33342 immunostaining..............................................................................................................................89 
5.3 Conclusion ........................................................................................................................................95 
6 DISCUSSION AND CONCLUSIONS................................................................... 96 
6.1 Results Summary .............................................................................................................................97 
Jessica C Lawson 2010 
6 
 
6.2 Novel algal compounds as potential anti-cancer and anti-CSC agents and identification of 
potential hit compounds .............................................................................................................................. 101 
6.3 A hit-to-target approach for screening potential anti-cancer and anti-CSC agents ..................... 103 
6.4 Importance of identifying anti-CSC and anti-breast CSC agents ................................................. 106 
7 REFERENCES .................................................................................................. 108 
8 APPENDICES .................................................................................................... 123 
8.1 APPENDIX 1 ................................................................................................................................. 124 
8.1.1 Reagents Used .......................................................................................................................... 124 
8.1.2 Compound Dilution Calculations ............................................................................................... 125 
8.2 SDS-PAGE Resolving and Stacking Gel Constituents .................................................................. 126 
8.2.1 12% Resolving Gel ................................................................................................................... 126 
8.2.2 4% Stacking Gel ....................................................................................................................... 126 
8.3 APPENDIX 2 ................................................................................................................................. 127 
8.3.1 IC50 calculations from graphs generated from MTT assays in MCF12A and MCF7 cells ............ 127 
8.4 APPENDIX 3 ................................................................................................................................. 133 
 
 
Jessica C Lawson 2010 
7 
 
List of Figures 
 
Figure 1: Schematic representation of the proposed origins of breast CSC. ......... 25 
Figure 2: Reduction of MTT by metabolically active cells ............................... 37 
Figure 3: Optimisation of the MTT assay on MCF7 cells using paclitaxel. ............ 51 
Figure 4: Determination of IC50 values of paclitaxel in MCF12A and MCF7 cells..... 52 
Figure 5: Determination of IC50 values of RUMB-001 in MCF12A and MCF7 cells. ... 53 
Figure 6: Determination of IC50 values of RUMB-002 in MCF12A and MCF7 cells. ... 54 
Figure 7: Determination of IC50 values of RUMB-003 in MCF12A and MCF7 cells. ... 55 
Figure 8: Determination of IC50 values of RUMB-004 in MCF12A and MCF7 cells. ... 56 
Figure 9: Determination of IC50 values of RUMB-005 in MCF12A and MCF7 cells. ... 57 
Figure 10: Determination of IC50 values of RUMB-007 in MCF12A and MCF7 cells. .. 58 
Figure 11: Determination of IC50 values of RUMB-008 in MCF12A and MCF7 cells. .. 59 
Figure 12: Determination of IC50 values of RUMB-010 in MCF12A and MCF7 cells. .. 60 
Figure 13: Determination of IC50 values of RUMB-015 in MCF12A and MCF7 cells. .. 61 
Figure 14: Determination of IC50 values of RUMB-017/018 in MCF12A and MCF7 cells.
............................................................................................. 62 
Figure 15: A comparison of the average cytotoxicity of the marine algal compounds 
in MCF12A (blue) and MCF7 (red) cells. ............................................ 63 
Figure 16: Different approaches available for the determination of toxicity to CSC
............................................................................................. 74 
Figure 17: Confirmation of the presence of the side population in MCF7 cells using 
flow cytometry .......................................................................... 76 
Figure 18: Comparison of the average percentage of the Hoechst 33342-excluding 
cells in MCF7 cells treated with selected marine algal compounds. .......... 77 
Figure 19: The effect of the priority compounds on the relative proportions of the 
ABCG2+ population in MCF7 cells .................................................... 81 
Figure 20: Simplified schematic diagram showing the convergence of extrinsic and 
intrinsic apoptotic pathways. ........................................................ 86 
Figure 21: Detection of PARP cleavage in MCF7 cells after treatment with the 
priority compounds using SDS-PAGE and Western blot analysis. ............... 88 
Figure 22: Representative of (normal) non-apoptotic (A) and apoptotic (B) nuclei in 
MCF7 cells using Hoechst-33342 staining. .......................................... 91 
Figure 23: Identification of Apoptotic Nuclei by Hoechst 33342 staining in MCF7 
cells treated with novel indigenous compounds .................................. 92 
Figure 24: Determination of the IC50 value of RUMB-001 in MCF12A (A) and MCF7 (B) 
cells ...................................................................................... 128 
Figure 25: Determination of the IC50 value of paclitaxel (1), RUMB-001 (2) and 
RUMB-002 (3) in MCF12A (A) and MCF7 (B) cells. ................................ 129 
Figure 26: Determination of the IC50 value of RUMB-003 (1), RUMB-004 (2) and 
RUMB-005 (3) in MCF12A (A) and MCF7 (B) cells. ................................ 130 
Figure 27: Determination of the IC50 value of RUMB-007 (1), RUMB-008 (2) and 
RUMB-010 (3) in MCF12A (A) and MCF7 (B) cells. ................................ 131 
Figure 28: Determination of the IC50 value of RUMB-015 (1) and RUMB-017/018 (2) 
in MCF12A (A) and MCF7 (B) cells................................................... 132 
Figure 29: Comparison of the percentage of ABCG2+ cells present in MCF7 cells 
after treatment with the priority compounds. ................................... 133 
Jessica C Lawson 2010 
8 
 
List of Tables 
 
Table 1: The code, name, structure, molecular mass and source of the compounds 
used in the anti-cancer and anti-cancer stem cell analyses .................... 35 
Table 2: Codes, names, structures and IC50 values in MCF12A and MCF7 cells of 
selected marine algal priority compounds and paclitaxel ...................... 68 
Table 3: A summary of the cytotoxicity of the algal compounds in MCF12A and MCF7 
cells and the effect of the priority compounds on MCF7 SP cells.............. 98 
Table 4: Reagents Used ....................................................................... 124 
Table 5: Stock concentrations (mM) of novel marine compounds dissolved in DMSO
............................................................................................ 125 
Table 6: Amount (µl) of DMEM added to 1 µl of stock compound to give a 1 mM .. 125 
Table 7: Concentrations of priority compounds used in treatment of MCF7 cells to 
determine the effect of these compounds on the MCF7 side population ... 133 
 
 
 
 
 
Jessica C Lawson 2010 
9 
 
Acknowledgements 
 
I would like to express my deepest gratitude to my supervisor Dr Adrienne Edkins 
and my co-supervisor Professor Gregory Blatch for their enduring support and 
guidance over the last two years, both in the lab and out. Their approachability, 
friendliness and willingness to help at every stage made this experience as fulfilling 
as possible and I extremely am grateful to them. 
 
I would like to thank all the members of the Biomedical Biotechnology Research 
Unit, especially Mrs Sarah Terry, Dr Earl Prinsloo and Dr Eva-Rachele Pesce, for all 
their assistance and support but especially for their friendship. 
 
In addition I would like to thank Dr Denzil Beukes of the Rhodes University 
Pharmacy Department for the kind gift of the algal compounds used in this study, 
Dr Maryna van de Venter and her students at Nelson Mandela Metropolitan 
University for their help with certain assays and Dr Sharon Prince and the members 
of the T-box Research Group at the University of Cape Town for the gift of the 
MCF12A and MCF7 cells and for welcoming me in to their laboratory during my 
research visit to Cape Town. I would also like to acknowledge Ronnie Dreyer from 
the University of Cape Town for his assistance with flow cytometry. 
 
I would like to thank all the organisations that have funded me during the course of 
this study, namely the Cancer Research Institute of South Africa, the National 
Research Foundation, the Ernst and Ethel Eriksen trust, Rhodes University for the 
Henderson Scholarship and the Deutscher Akademischer Austausch Dienst. 
Jessica C Lawson 2010 
10 
 
Outputs 
 
Publications 
Lawson, J. C., Blatch, G. L. and Edkins, A. L. (2009) Cancer stem cells in breast 
cancer and metastasis. Breast Cancer Research and Treatment, 118, 241-254. 
 
Prinsloo, E., Cooper, L. C., Moyo, B., de la Mare, J.-A., Lawson, J. C., Edkins, A. 
and Blatch, G. L. (2010). Heat Shock Proteins in Normal and Cancer Stem Cell 
Biology: Implications for Regenerative and Chemotherapeutic Medicine. Book 
chapter in preparation. 
 
Conference Outputs 
Poster and oral presentation: Symposium on Chemico- and Biomedicinal Research, 
Thursday 5 November 2009, Rhodes University 
 
Oral presentation: Eastern Cape South African Society of Biochemistry and 
Molecular Biology Conference, Friday 6 November 2009, Nelson Mandela 
Metropolitan University 
Jessica C Lawson 2010 
11 
 
Author’s Declaration 
 
I, Jessica Clair Lawson, declare that this thesis, which I now submit for the degree 
of Master of Science, is my own unaided work and has not been submitted for a 
degree at any other university. During the course of this study a review pertaining 
to the work presented in this thesis was published (see Lawson, J. C., Blatch, G. L. 
and Edkins, A. L. (2009) Cancer stem cells in breast cancer and metastasis. Breast 
Cancer Research and Treatment, 118, 241-254). 
 
Signed: ____________________ 
 
on this _____ day of __________________ 2010 
Jessica C Lawson 2010 
12 
 
Abbreviations 
 
17-AAG  17-Allylamino-17-demethoxygeldanamycin 
17-DMAG 17-Dimethylaminoethylamino-17-demethoxygeldanamycin 
Hydrochloride  
ABCG2 ATP-binding Cassette Transporter sub-family G member 2 
ALDH1  Aldehyde dehydrogenase 1 
AML  Acute Myeloid Leukaemia  
BRCA1  Breast Cancer Susceptibility Gene 1 
BRCA2  Breast Cancer Susceptibility Gene 2 
CASY  Cell Counter and Analyser System 
CO2  Carbon Dioxide 
COX-2  Cyclooxygenase 2 
CSC   Cancer Stem Cells 
CXCR4  CXC Chemokine Receptor 4 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic Acid 
dUTP  Deoxyuracil Triphosphate 
ER  Oestrogen Receptor  
FACS  Fluorescence Assisted Cell Sorting 
FCS  Foetal Calf Serum 
FITC  Fluorescein Isothiocyanate 
H2O2  Hydrogen Peroxide 
HER-2  Human Epidermal Growth Factor Receptor 2 
HIV/AIDS Human Immunodeficiency Virus/ Acquired immune deficiency 
syndrome 
HRP  Horseradish Peroxidase 
MMTV  Mouse Mammary Tumour Virus 
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide 
NADH  Nicotinamide Adenine Dinucleotide 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NMR  Nuclear Magnetic Resonance 
NOD/SCID Non-Obese Diabetic/ Severe Combined Immune Deficiency 
NSP  Non-Side Population 
Jessica C Lawson 2010 
13 
 
PARP  Poly(ADP-ribose) Polymerase 
PBS  Phosphate Buffered Saline 
PR  Progesterone Receptor 
RNAi  RNA Interference 
SAR  Structure Activity Relationship 
SDS-PAGE Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SP  Side Population 
TBST  Tris-Buffered Saline with 0.1% Tween-20 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
VEGF  Vascular Endothelial Growth Factor 
Jessica C Lawson 2010 
14 
 
 
1 LITERATURE REVIEW 
Jessica C Lawson 2010 
15 
 
1.1 Cancer 
Cancer is a serious disease and is the second most common cause of death worldwide, 
exceeded only by heart disease, and kills more of the world‟s population than tuberculosis, 
malaria and HIV/AIDS combined (Singh et al., 2004). A total of 12.5% of deaths worldwide 
is due to cancer and it was estimated that there would be 12.1 million new cancer cases 
worldwide in 2007, 45% in developed countries and the remaining 55% in developing 
countries (Bao et al., 2006b; Bertram, 2000; Garcia et al., 2007). It was predicted that there 
would be 7.6 million deaths as a result of cancer in 2007, 38% in developed countries and 
62% in developing countries (Garcia et al., 2007). In Southern Africa in particular, there were 
an estimated 78 000 new cancer cases and over 54 000 deaths as a result of cancer and the top 
three diagnosed malignancies in Southern Africa are cervical, breast and prostate cancers 
respectively (Garcia et al., 2007). 
 
1.2 Cancer Development 
There are six properties that make cells capable of cancerous growth; they are not under the 
control of signals that regulate cell proliferation, they are resistant to apoptosis, they 
overcome limitations on proliferation by avoiding replicative senescence and evading 
differentiation, they are genetically unstable, they are able to invade surrounding tissues and 
they are capable of metastasis (Bertram, 2000; Fleming, 2003). In order for a cancerous 
tumour to develop, cancer cells must overcome replicative cell senescence and become 
„immortalised‟ i.e. continue dividing indefinitely (Hornberg et al., 2006). Tumours are only 
considered to be cancerous if they are capable of metastasis and colonising surrounding tissue 
(de Castro Junior et al., 2006; Hornberg et al., 2006). Even though most cancers are thought 
to be monoclonal, the development of cancer takes place over many years and involves 
multiple processes (Bertram, 2000; Garcia et al., 2007; Hart, 2004). The original abnormal 
cell must undergo some change that allowed it to grow much faster than „normal‟ cells in the 
same tissue and this property had to be passed on to subsequent daughter cells (Bertram, 
2000; Garcia et al., 2007; Hart, 2004; Singh et al., 2004). For cancer to successfully develop, 
numerous but independent changes must occur in this one cell (Bertram, 2000; Garcia et al., 
2007; Hart, 2004). Most cancers are thought to be a result of genetic mutations in the DNA of 
the cancerous cells and these mutations can be a result of internal elements, such as inherited 
mutations, and external elements, including chemical carcinogens and viruses (Bertram, 2000; 
Garcia et al., 2007; Hart, 2004). The daughter cells of the original aberrant cell must then 
undergo further mutations to allow them to divide uncontrollably and thrive in the tumour 
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environment and eventually outnumber the healthy cells in the tissue (Bertram, 2000; Garcia 
et al., 2007; Hart, 2004). 
 
1.3 Breast Cancer 
Breast cancer is the most common form of cancer diagnosed in women worldwide, affecting 
an estimated 10% of women, with over 1.3 million new cases and over 400 000 deaths 
predicted for 2007 (Garcia et al., 2007; Imyanitov and Hanson, 2004). There are different 
factors that contribute to the incidence of breast cancer, including advanced age (Garcia et al., 
2007; Imyanitov and Hanson, 2004), high oestrogen levels (Clemons, 2001), extensive 
chromosomal mutations (Lerebours and Lidereau, 2002), breast cancer genes BRCA1 and 
BRCA2 (especially significant in hereditary breast cancer) (Nathanson et al., 2001), DNA 
hypermethylation (Widschwendter and Jones, 2002) and mutations in the mitochondrial DNA 
of epithelial mammary cells (Bianchi et al., 2001). Also being re-considered is the potential 
viral origin of human breast cancer (Mant and Cason, 2004; Mant et al., 2004). Two of the 
most commonly reported viruses investigated as potential causal agents in breast cancer are 
the Epstein Barr virus and mouse mammary tumour virus (MMTV). There is evidence of 
genetic material from the Epstein-Barr virus present in 21% of breast tumours analysed in 
1995 (Labrecque et al., 1995) and in another 100 invasive breast carcinomas, 51% of tumours 
were positive for the Epstein-Barr viral genome while 90% of healthy tissue adjacent to the 
tumours tested was negative for the viral genome (Bonnet et al., 1999). More recently, genes 
encoding the envelope for MMTV, which, as its name suggests, causes mammary tumours in 
mice, were found in 40% of human breast cancer patients tested but the same genes were 
present in only 4% of normal breast tissue samples tested (Cotterchio et al., 2002). Another 
study showed evidence of the MMTV-env gene in between 38% and 40% of breast cancer 
samples tested but the gene was not present in any of the healthy tissue tested (Wang et al., 
1998; Wang et al., 1995). It is not known, however, whether these viruses are responsible for 
the cancer that developed or whether they are there for another reason (Brower, 2004). 
 
1.3.1 Breast cancer subtypes 
Normal breast epithelium, the component of the mammary gland that gives rise to breast 
cancer, contains a basal layer of myoepithelial cells and an inner layer of luminal cells and 
human breast cancers are either myoepithelial, basal or luminal (Daniel and Smith, 1999). 
Gene expression profiling has enabled the classification of breast tumours into subtypes, 
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namely luminal, basal and HER-2 (human epidermal growth factor receptor 2) over-
expressing tumours (Cheang et al., 2008; Jumppanen et al., 2007). Luminal breast tumours 
express progesterone receptor (PR), oestrogen receptor (ER) and HER-2, can often be treated 
successfully  with hormone therapy and in general have a good prognosis (Adelaide et al., 
2007; Phipps et al., 2008). Basal breast tumours carry the „triple negative‟ phenotype; that is 
they do not express ER, PR or HER-2 and are considered to be highly aggressive and have a 
much poorer prognosis than their luminal counterparts (Adelaide et al., 2007; Phipps et al., 
2008). Basal tumours account for between 10% and 15% or breast tumours, are associated 
with younger patient age, have no specific treatment and have high metastatic potential 
(Adelaide et al., 2007; Jumppanen et al., 2007; Phipps et al., 2008). HER-2 over-expressing 
breast tumours also have a poorer clinical prognosis than luminal breast tumours but unlike 
basal tumours, HER-2 positive tumours do have specific and standardized treatments such as 
trastuzumab (discussed further later) and lapatinib (Adelaide et al., 2007; Tzong-Der et al., 
2005). The over-expression of HER-2 is observed in between 25% and 30% of breast cancers 
(Hortobagyi et al., 1999; Wilson et al., 2005) but the development of resistance to 
trastuzumab is a problem. Between 66% and 88% of breast cancer patients who initially 
respond to trastuzumab develop resistance and present with disease progression within one 
year of being treated with trastuzumab (Nahta and Esteva, 2006; Nahta et al., 2006). Another 
kind of breast cancer, myoepithelial breast cancers, are rare and aggressive and little is known 
about their aetiology or the long-term prognosis of patients with myoepithelial tumours 
following treatment (Behranwala et al., 2004; Woo et al., 2005). 
 
 
1.4 Theories of cancer development 
 
1.4.1 Breast Cancer Development and Progression 
 
1.4.1.1 Stochastic model of cancer development and sporadic and familial 
breast cancer  
The theory of cancer development that has informed the way cancer has been treated over the 
last few decades holds that for cells to become malignant they must be subjected to a series of 
mutations in the cell‟s DNA. The damage to the genome can be a result of internal or external 
factors. Internal factors that can contribute to genome damage include faulty DNA replication 
and unstable DNA base pairs. External factors that may contribute to mutations in the genome 
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include chemical carcinogens, exposure to UV radiation and, in some cancers, viruses 
(Bertram, 2000; Fleming, 2003; Hart, 2004).  
 
The mutations that lead to malignancy are those mutations that confer the ability to escape 
regular homeostatic mechanisms of the cell and are generally those that abolish the function 
of a certain gene, called a tumour suppressor gene, or those that increase the expression or 
activation of a gene, called an oncogene (Armitage and Doll, 1961; Bertram, 2000). For a 
cancer to develop, four to seven independent mutations need to occur within genes crucial to 
cellar processes (Armitage and Doll, 1961; Fleming, 2003). A cell containing the initial 
mutation needs to replicate and accumulate multiple mutations that will allow the cell to 
replicate in an uncontrolled manner and invade surrounding tissues. This depends on clonal 
expansion, a process by which the number of cells increases exponentially as the production 
of daughter cells, all arising from a single original cell, progresses, as the probability of the 
cell carrying the initial mutation acquiring another mutation in the necessary location is 
almost negligible (Armitage and Doll, 1961; Bertram, 2000). Clonal expansion continues so 
that the mutations necessary for cancer development can be accumulated (Armitage and Doll, 
1961; Bertram, 2000). 
 
Sporadic breast cancer is the result of genetic alterations to the genomic material in the 
somatic breast cells rather than a result of an inherited, or germline, mutation (Lerebours and 
Lidereau, 2002; Ma et al., 2003). Little is known about the molecular basis and genetic events 
involved in the stochastic development of sporadic breast cancer, partly due to the vast 
clinical, biological and geographical diversity of breast cancers (Lerebours and Lidereau, 
2002; Ma et al., 2003). According to the stochastic theory of cancer development the 
development and progression of breast cancer is a result of a series of accumulated mutations 
which, due to clonal expansion, result in successively aggressive clones that eventually lead to 
an invasive carcinoma (Lerebours and Lidereau, 2002). The progression of sporadic breast 
cancer is believed to be linear, starting with a premalignant atypical ductal hyperplasia which 
develops into a preinvasive ductal carcinoma in situ, which in turn develops into an invasive 
ductal carcinoma (Ma et al., 2003). The activation of oncogenes and inactivation of tumour 
suppressor genes is thought to be an early event in breast cancer development, followed by 
mutations in at least four other genes (Kenemans et al., 2004). Oncogenes commonly 
activated in sporadic breast cancers include MYC, which encodes a transcription factor 
involved in cell growth, CCND1, which codes for cyclin D1, and HER. Tumour suppressor 
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genes commonly inactivated in breast cancers include TP53, which codes for a transcription 
factor involved at many stages in the cell cycle and RB1, the retinoblastoma gene (Kenemans 
et al., 2004; Lerebours and Lidereau, 2002; Ma et al., 2003).  
 
Approximately 4% to 9% of breast cancers are inherited and mutations in two major breast 
cancer susceptibility genes, BRCA1 and BRCA2, account for the majority of inherited breast 
cancers (Joseph et al., 1996). BRCA1 has been mapped to a region on chromosome 17q and 
BRCA2 to the q12-13 region on chromosome 13 (Joseph et al., 1996) and mutations in these 
two genes are rare in sporadic breast cancer (Lerebours and Lidereau, 2002). Both BRCA1 
and BRCA2 are tumour suppressor genes and are inactivated by their mutations in hereditary 
breast cancer, although not all hereditary breast cancers carry mutations in these genes 
(Cheang et al., 2008; Joseph et al., 1996). Hereditary BRCA1 breast cancers resemble basal 
breast cancers and are more frequently aneuploid than other hereditary breast cancers (Cheang 
et al., 2008; Joseph et al., 1996; Phipps et al., 2008). The death rate and tumour recurrence 
associated with BRCA1 are also lower than those observed in BRCA2 breast cancers (Joseph 
et al., 1996). 
 
1.4.1.2 Cancer stem cell theory of cancer development and breast cancer stem 
cells 
An alternative model of cancer development that has gained popularity over the last few years 
is the Cancer Stem Cell theory of cancer development. Cancer stem cells (CSC) are 
tumorigenic cells capable of self-renewal to produce another CSC, as well as differentiation to 
produce non-tumorigenic cancer cells. The cancer stem cell theory proposes that during 
cancer development the genes involved in stem cell self-renewal regulation are disturbed (Al-
Hajj et al., 2004). The recent discovery of CSC has changed the way scientists think about 
cancer, which in turn has implications for how the treatment of this disease is approached.  
The stem cell origin of cancer hypothesizes that CSC are capable of self-renewal, are resistant 
to chemotherapy and are able to repopulate the tumour mass after chemotherapy (Marotta and 
Polyak, 2009; Wicha et al., 2006). CSC were first discovered in acute myeloid leukaemia 
(AML) (Bonnet and Dick, 1997) and have since been shown to exist in B and T acute 
lymphoblastic leukaemia (Cobaleda et al., 2000; Cox et al., 2004), as well as solid tumours 
including colon and brain tumors (Bao et al., 2006a; Bao et al., 2006b; Dalerba et al., 2007; 
Dick, 2003; Piccirillo et al., 2006) and in pancreatic, lung, prostate and breast cancers (Al-
Hajj et al., 2003; Kim et al., 2005; Li et al., 2007; Xin et al., 2005).  
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The origin of CSC remains to be conclusively determined; however two theories have been 
proposed. One theory proposes that normal stem cells, which are long-lived, undergo some 
mutation which gives rise to CSC while the other theory poses that a differentiated cell 
undergoes a „de-differentiation‟ process through which it gains stem-like properties (Burns et 
al., 2005; Sell, 1993). It has been shown that after long-term culture of four to five months, 
normal human adult mesenchymal stem cells can give rise to stem cells with cancerous 
properties, supporting the suggestion that CSC are a result of a genetic alteration in normal 
stem cells (Rosland et al., 2009; Rubio et al., 2005; Shi et al., 2007). There is also 
experimental evidence supporting the idea that a differentiated cell can be induced to de-
differentiate into a pluripotent cell with stem-like properties, where pluripotent stem cells 
were induced from adult mouse fibroblasts using four factors including Oct-3/4 under 
embryonic stem cell conditions (Takahashi and Yamanaka, 2006). These cells expressed 
embryonic stem cell markers and showed the same growth and morphology characteristics as 
embryonic stem cells (Takahashi and Yamanaka, 2006). Also, upon injection into nude mice, 
these cells gave rise to tumors (Takahashi and Yamanaka, 2006). 
The way in which the human mammary gland changes and develops suggests the presence of 
a stem cell population within the breast tissue and it has been experimentally shown in mice 
that a functional mammary gland can be generated in a cleared mammary fat pad from a 
single cell (Shackleton et al., 2006; Wicha et al., 2003). The cells capable of doing this were 
found in the Lin-CD29hiCD24+ population within breast tissue and were also found to be 
capable of self-renewal and are multi-potent and have thus been defined as breast stem cells 
(Shackleton et al., 2006). It has since been suggested that a hierarchical relationship exists 
between human breast stem cells and their differentiated progeny (Shackleton et al., 2006) 
and the existence of an adult breast stem cell lends support to the idea that breast CSC may 
arise from a transformed adult breast stem cell. 
 
There is evidence for the existence of breast CSC within breast tissue in the human mammary 
gland, first reported by Al-Hajj and colleagues in 2003 using pleural effusions and tumour 
implantations (Al-Hajj et al., 2003). It was shown that only a small subpopulation of cells, 
namely those with the phenotype CD44+CD24-, was able to initiate the formation of a new 
tumour when a small number of these cells, sometimes as few as 100, was injected into the 
cleared mammary fat pad of non-obese diabetic severe combined immunodeficient 
(NOD/SCID) mice. The resultant tumours also contained a subpopulation of CD44+CD24- 
cells (Al-Hajj et al., 2003). Cells with different phenotypes, such as CD44+CD24+, were 
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unable to do this, even when tens of thousands of cells were used (Al-Hajj et al., 2003). This 
is supported by another study in which the stem-like properties of CD44+CD24- cells were 
confirmed and the cells were propagated in vitro as anchorage-independent mammospheres 
(Abraham et al., 2005), a characteristic typical of normal breast stem cells (Dontu et al., 
2003). As with other CSC, there is still uncertainty as to the origin of breast CSC; whether 
they arise from a transformed normal mammary stem cell or whether from a differentiated 
breast cell that has undergone dedifferentiation and malignant transformation (Figure 1). 
There is experimental evidence to support the proposal that breast CSC arise from a normal 
breast stem cell having transformed (Boulanger and Smith, 2001; Taketo et al., 1991). FVB/N 
mice, an inbred mouse strain favoured for transgenic analyses (Taketo et al., 1991), show 
decreased susceptibility to MMTV-induced breast cancer if the proliferative capacity of the 
normal mammary stem cells in situ is decreased (Boulanger and Smith, 2001). The mammary 
gland, which is comprised of an extensive network of ducts, undergoes massive changes and 
expansion during puberty unlike other organs, which for the most part fully develop during 
foetal development (Melchor and Smalley, 2008; Sternlicht, 2006).  
 
CSC exist within a small subpopulation of tumour cells distinct from the main tumour cells 
known as the “side population” (SP), a group of cells defined by the ability to actively 
exclude the fluorescent dye Hoechst. SP cells are known to express high levels of ABC 
transporters, especially ABCG2, and these ABC transporters are responsible for the exclusion 
of Hoechst 33342 from the SP cells (Hirschmann-Jax et al., 2004; Zhou et al., 2001). CSC do 
not constitute the entire side population and reports differ with respect to the proportion of the 
side population comprised of CD44+CD24- cells. The cancer stem cell population within a 
tumour has been proposed to comprise only a small percentage of the total tumour, namely 
between 0.01% and 2% of the tumour (Fillmore and Kuperwasser, 2008), as observed in 
AML where the proportion of the total tumour cells comprised of alleged CSC was 0.2% 
(Bonnet and Dick, 1997) however, this is not always seen in experimental data. For example, 
cells expressing CD133 have been proposed as potential brain CSC and in a study conducted 
by Singh and colleagues cells expressing CD133 comprised between 3.5% and 45.4% of the 
total tumour mass from different patients (Singh et al., 2003). In addition, the cancer stem cell 
population described by Al-Hajj made up between 11% and 35% of the total tumours (Al-Hajj 
et al., 2003) while in another immunohistochemical study a significant proportion of the 
breast tumour samples (12.4%) has a CD44+CD24- population of greater than 10% (Mylona et 
al., 2008). Also worth noting is that the CD44+CD24- cancer stem cell-representative 
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phenotype seems to be predominant in BRCA1, tumours but the same cells are uncommon in 
HER2 positive tumours (Honeth et al., 2008). CD44+CD24- cells are present in normal breast 
epithelium in large numbers in the basal layer and so this may be the origin of cancer in basal 
and BRCA1 type cancers although these cells are not present in all types of breast tumours 
(Honeth et al., 2008). Are CD44+CD24- cells only tumour initiating cells in certain types of 
cancer and if so, what is the tumour initiator in breast tumours lacking CD44+CD24-, and 
where do they originate from? Another marker, aldehyde dehydrogenase 1 (ALDH1), has 
been used to separate fractions of breast tumours in tumour initiating and non-tumour 
initiating cells, although it is only found in 30% of breast tumours (Ginestier et al., 2007).  
 
One of the defining characteristics of CSC is their inherent resistance to chemotherapy (Eyler 
and Rich, 2008). The chemoresistance of CSC allows for their survival during treatment and 
as such enables them to initiate tumour repopulation and therefore patient relapse, providing a 
major challenge in the effective treatment of cancer (Eyler and Rich, 2008). One such 
reported instance of this is reported in a study on the effect of conventional chemotherapy 
drugs on the CD44+CD24- population in breast cancer biopsy samples. Patients with advanced 
breast cancer were subjected to 12 weeks of treatment with docetaxel or doxorubicin and 
cyclophosphamide. The percentage of CD44+CD24- cells present in the tumour biopsies 
before treatment commenced was 4.7%. After 12 weeks of treatment the proportion of these 
cells had increased to 13.6% and these cells were capable of forming anchorage-independent 
mammospheres, suggesting that enrichment for CSC had occurred (Li et al., 2008). In 
addition to this Li and colleagues established xenografts of the breast cancer biopsies in SCID 
mice. In the mice transplanted with pre-chemotherapy breast cancer biopsy samples, 29% of 
the xenografts formed tumours whereas in the mice transplanted with post-chemotherapy 
breast cancer biopsy samples 50% of the xenografts formed tumours, suggesting that the cells 
that survived treatment with the chemotherapy drugs are enriched for tumorigenic cells (Li et 
al., 2008). The results from the studies by Al-Hajj and colleagues (2003) and Li and 
colleagues (2008), assuming they are representative of the environment and events in a 
tumour in a breast cancer patient, show that these cells are tumorigenic and resistant to 
chemotherapy, both considered to be properties of CSC. Understanding of the molecular 
mechanisms responsible for the observed chemoresistance in CSC may lead to treatments 
which either eradicate the CSC themselves or render the CSC susceptible to current 
chemotherapy treatments (Eyler and Rich, 2008). CSC exist in a small side population within 
the tumour and these side population cells express a high level of ABC transporter proteins, 
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especially ABCG2, a multi-drug resistant transporter that may confer some of the observed 
chemoresistance to the side population cells (Hirschmann-Jax et al., 2004; Zhou et al., 2001). 
The expression of ABCG2 by the cancer stem cell-containing SP has been exploited as a 
means of identifying the SP and is currently being used as a marker for the side population 
(Challen and Little, 2006; Goodell et al., 1996). 
 
The part played by the CD44+CD24- phenotype in breast CSC is still controversial but there it 
has been shown that chemotherapeutic treatment results in an increase in the percentage of 
CD44+CD24- subpopulation cells in breast cancer patients after chemotherapy, suggesting that 
they are resistant to chemotherapy (Li et al., 2008) in accordance with the stem cell theory of 
cancer. In addition to CD44+CD24-, the expression of ALDH1 and CD133 are being used as 
markers for breast CSC (Ginestier et al., 2007; Wright et al., 2008). As already mentioned, 
breast CSC display some of the properties that define normal breast stem cells. It is not 
unreasonable then to believe that both breast stem cells and breast CSC are reliant on the 
same pathways for their self-renewal and asymmetric division. Integrins, in particular β1 
integrin, have already been suggested to be involved in the same processes in breast CSC. 
Knockout of the β1 integrin has been shown to obstruct tumorigenesis in a transgenic mouse 
model of human breast cancer. Moreover, α-6 integrin was recently shown to be critical for 
tumorigenic cells isolated from the side population of MCF7 cells to generate tumours in 
SCID mice (Cariati et al., 2008). 
 
1.5 Breast CSC and metastasis 
Metastasis is the most common cause of mortality in breast cancer patients but there is as yet 
no standardized treatment (Freudenberg et al., 2009; Gralow, 2005). The most common sites 
of metastasis in breast cancer patients are the bone marrow and lungs (Abraham et al., 2005; 
Kang et al., 2003; Mastro et al., 2007). If CSC are responsible for the initiation and 
maintenance of tumours, this raises the question of whether they are involved in metastasis 
and if so, to what extent.  
 
The expression of CD44 is believed to be a marker of breast CSC (Al-Hajj et al., 2003) and 
activation of CD44 results in cell motility, promotion of cellular adhesion and activation of 
cell survival mechanisms (Draffin et al., 2004). A potential role of CD44 expression in 
metastasis has recently been described by Draffin and colleagues. They detected CD44 
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expression in a metastatic breast cancer cell line MDA-MB-231 but did not detect it in the 
weakly invasive MCF7 breast cancer cell line (Draffin et al., 2004). In addition to this, down-
regulation of CD44 expression in the metastatic cell line by RNAi resulted in decreased 
invasiveness and adherence to human bone marrow endothelial cells, while expression of 
CD44 in the MCF7 cell line after transfection resulted in increased cellular adhesion to human 
bone marrow endothelial cells (Draffin et al., 2004). This evidence suggests a role for CD44 
in breast cancer metastasis, especially to the bone marrow (Draffin et al., 2004), which is one 
of the main development sites of breast cancer metastasis (Kang et al., 2003). 
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Figure 1: Schematic representation of the proposed origins of breast CSC. 
 (A) A stem cell within the breast tissue undergoes transformation to become a malignant breast cancer stem cell. 
(B) A differentiated breast cell is induced to a pluripotent cell with malignant properties, thus a breast cancer 
stem cell. The breast CSC are capable of self-renewal and asymmetric division such that the cancer stem cell 
population is maintained and proliferation of invasive cancer cells occurs (Boulanger and Smith, 2001; Ponti et 
al., 2006; Shackleton et al., 2006; Taketo et al., 1991). 
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Osteopontin, one of the ligands recognised by CD44, is a sialic rich phosphoglycoprotein and 
evidence of its involvement in metastasis is growing (Chakraborty et al., 2008; Suzuki et al., 
2007; Wai and Kuo, 2004). In breast cancer in particular, osteopontin overexpression triggers 
the expression of vascular endothelial growth factor (VEGF), thereby inducing tumour 
invasion, progression, angiogenesis and metastasis (Chakraborty et al., 2008; Tuck et al., 
1999; Tuck et al., 1998; Tuck et al., 1997). Osteopontin is able to induce breast epithelial cells 
to invade and migrate (Tuck et al., 1999; Tuck et al., 1998) while inhibition of osteopontin in 
the highly metastatic breast cancer cell line MDA-MB-231 has been shown to decrease the 
metastatic ability of these cells (Adwan et al., 2004). Breast CSC are believed to express 
CD44, the receptor for osteopontin, a matrix protein often expressed at the sites of breast 
cancer metastases. The interaction between CD44 and osteopontin may result in the attraction 
of metastatic cancer cells to certain tissues in the body (Lawson et al., 2009). Osteopontin is 
expressed in, among other tissues, bone marrow and lung tissue (Brown et al., 1992) and so it 
is possible that osteopontin facilitates the homing of metastatic breast cancer cells to these 
tissues. If breast CSC are responsible for metastasis then it is also possible that the CD44 
expressed on the surface of the breast CSC interacts with the osteopontin present in the tissues 
at the sites of metastasis (Lawson et al., 2009). CD24, on the other hand, is believed to 
decrease the metastatic potential of cells by inhibiting the migration-inducing activity of 
chemokine receptor CXCR4 (Darash-Yahana et al., 2004). The proposed breast CSC are 
CD24 deficient, which may positively influence the migration, and thus metastatic potential, 
of these cells (Schabath et al., 2006). Furthermore, the majority (71%) of cells in early bone 
marrow metastases of breast cancer patients have been shown to be CD44+CD24- cells (Balic 
et al., 2006). The evidence of the involvement of CD44 and osteopontin in breast cancer 
metastasis and well as the absence of metastasis-inhibiting CD24 on the putative breast CSC 
supports the theory that breast CSC are responsible, at least in part, for breast cancer 
metastases. 
 
1.6 Current Breast Cancer Treatments and Limitations 
Even though more is known today about the biology of different tumours, there has been little 
marked increase in the last two decades in the survival of patients whose cancer was 
diagnosed at an advanced stage (Etzioni et al., 2003). The decrease observed in the number of 
deaths as a result of cancer is attributed primarily to prevention and early diagnosis rather than 
the successful treatment of advanced cancers (Etzioni et al., 2003). Current cancer treatments 
include surgery, chemotherapy and radiation. Surgeries performed on cancer patients include 
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preventative surgery, where tissue that has a high chance of becoming cancerous is removed, 
curative surgery, where it is expected that the entire tumour can be removed by surgery and 
palliative surgery which aims to treat complications that arise as a result of advanced cancers. 
There are different chemotherapeutic drugs that target the different stages of cancer and there 
is still much research into the alteration of the cellular processes involved in each of these 
stages and potential ways of blocking them. Angiogenesis, for example, can be halted by 
bevacizumab (Avastin), a compound that blocks vascular endothelial growth factor signals 
from the tumour (Velcheti et al., 2006). Other drugs that have been found to interfere with the 
angiogenesis of a tumour are cyclophosphamide (Neosar, Cytoxan), paclitaxel (Taxol) and 
COX-2 inhibitors celecoxib and thalidomide (Celebrex, Thalomid) (Brock, 1996; Fuchs and 
Johnson, 1978; Solomon et al., 2005). Imatinib, more commonly known as the drug Gleevec, 
inhibits the tyrosine kinase Bcr-Abl in chronic myelogenous leukaemia and is also known to 
inhibit c-kit and PDGF-R (platelet-derived growth factor receptor) (Deininger and Druker, 
2003). Radiation therapy aims to damage cancer cells using ionizing radiation by subjecting 
the tumour to high-energy particle beams, for example gamma-rays, but unfortunately, as with 
chemotherapy, normal cells are also destroyed. 
 
Breast cancer is often diagnosed only after it has passed through the early and most treatable 
stages (Garcia et al., 2007; Imyanitov and Hanson, 2004). Currently, only 32% of women in 
southern Africa diagnosed with advanced breast cancer survive more than 5 years (Garcia et 
al., 2007). The majority of chemotherapy drugs currently employed in the treatment of breast 
cancer such as paclitaxel and doxorubicin are complex organic structures containing ring 
structures and nitrogen (Sigurdsson et al., 1986; Tian et al., 2004; Wang et al., 2006; Yayoi et 
al., 2009). There is currently no standardized treatment for metastatic breast cancer, which is 
the major cause of death in breast cancer patients (Gralow, 2005). Recently however, 
trastuzumab, a recombinant monoclonal antibody directed against the extracellular domain of 
HER-2, has been used to treat HER2-positive early and metastatic breast cancer with some 
success, especially when combined with traditional chemotherapeutic drugs (Emens, 2005; 
Hall and Cameron, 2009; Neyt et al., 2008). A response rate of up to 84% was seen in clinical 
trials when trastuzumab was used in conjunction with conventional chemotherapy drugs such 
as paclitaxel, doxorubicin and docetaxel with improved response duration, time to progression 
and survival (Hall and Cameron, 2009; Marty et al., 2005; Slamon et al., 2001). Whether 
trastuzumab acts by down-regulating HER-2 expression or by inhibiting HER-2 cleavage 
however, remains unknown (Hall and Cameron, 2009). While current cancer treatments often 
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appear initially successful, relapse occurs often.  It has been proposed that this relapse may be 
a result of the CSC, which are chemoresistant and thus unaffected by chemotherapy and 
remain behind after treatment and are able to repopulate the tumour. CSC, like other stem 
cells, exhibit the ability to self-renew and are resistant to chemotherapeutics due to a high 
level of expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL (Domen et al., 1998; 
Peters et al., 1998)  and the presence of multi-drug resistance transporters, for example 
ABCG2 (Zhou et al., 2001). A further disadvantage of many of the drugs used in 
chemotherapy is non-specific toxicity and therefore the adverse effect they have on other 
tissues. Chemotherapy can cause problems in the cardiovascular, respiratory, hepatic and 
gastrointestinal systems in a patient (Carr et al., 2008) and the ionizing beams used in 
radiation are also harmful to healthy cells. 
 
Humans have been using plants and other natural resources to treat diseases for centuries 
(Weldegerima, 2009).  Between 1981 and 2002, 62% of novel small molecules approved as 
chemotherapy drugs were natural products, derivatives thereof or synthetic replicas of natural 
products (Newman et al., 2003). The investigation of natural products for new drugs is 
ongoing. Paclitaxel, isolated from the Pacific yew tree Taxus brevifolia and docetaxel, 
isolated from the European yew tree, are both used in the treatment of breast cancer and are 
both natural products (Newman et al., 2003). In an analysis by Fabricant and Farnsworth, 122 
compounds with a defined chemical structure were identified, all of which were isolated from 
only 94 plant species (Fabricant and Farnsworth, 2001). While plants have historically been 
the main source of compounds with drug properties, marine organisms in particular are 
known to be a rich source of chemically and biologically diverse compounds, many of which 
may well prove to be effective anti-cancer agents (Valeriote et al., 1994; Weldegerima, 2009). 
Cytosine arabinoside, isolated from Cyptothecia crypto,  was the first compound of marine 
origin to be approved as an anti-cancer drug and is used in the treatment of acute myeloid 
leukaemia and non-Hodgkin‟s lymphoma (Mayer and Gustafson, 2003; Pigneux et al., 2007; 
Wang et al., 1997). Two other compounds of marine origin that have proven to have anti-
cancer activity are didemnin B from Trididemnum solidum which exhibited anti-cancer 
activity in kidney, ovarian and breast cancer (Mittelman et al., 1999; Rinehart et al., 1988; 
Taylor et al., 1992), and bryostatin from Bugula neritina, which exhibited anti-cancer activity 
in lung and prostate tumours and non-Hodgkin‟s lymphoma (Hornung et al., 1992; Kerr et al., 
1996). Didemnin B, however, caused allergic reactions in patients and clinical trials were 
terminated (Nuijen et al., 2000). There are, however, many other compounds isolated from 
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marine organisms that display anti-cancer activity as reviewed by Mayer and Gustafson 
(Mayer and Gustafson, 2003), and over the past 15 years several new experimental 
compounds of marine origin entered preclinical and clinical trials (Schwartsmann et al., 
2001). Halogenated monoterpenes are a class of small organic compounds produced only by 
Plocamium, Porteria and Ochtodes algal species (Naylor et al., 1983). Over 100 of these 
compounds have been identified, some of which have been shown to have anti-cancer activity 
even though they are chemically and structurally very different from current chemotherapy 
drugs (Naylor et al., 1983; Polzin et al., 2003). Species of the Plocamium genus produce both 
linear and cyclic halogenated monoterpenes as secondary metabolites (Afolayan et al., 2009). 
Of the ten compounds used in the research presented here, nine were halogenated 
monoterpenes isolated from Plocamium corallorhiza and Plocamium cornutum collected off 
the Eastern Cape coast of South Africa (Knott et al., 2005; Mann et al., 2007). These 
compounds have been demonstrated as having anti- cancer activity in human oesophageal 
cancer cell line WHCO1 (Knott et al., 2005; Mann et al., 2007). The remaining compound 
used in this study was sargaquinoic acid, a tetraprenylquinone isolated from the brown algae 
Sargassum heterophyllum that has been shown to have both the ability to induce apoptosis in 
human keratinocyte cell line HaCaT (Hur et al., 2008) and to induce neural differentiation in 
cells derived from a pheochromocytoma of rat adrenal medulla (Kamei and Tsang, 2003; 
Tsang et al., 2001). 
 
Chemotherapy regimens currently in use have adverse effects on healthy tissues in the body 
(Carr et al., 2008). There are over 200 chemotherapeutic agents in use and unfavourable side 
effects have been reported for the majority of these drugs, with the long-term side effects of 
others, such as trastuzumab, being widely unknown (Carr et al., 2008). It is difficult to 
develop a standardized treatment for the different breast cancer subtypes based on the 
characteristics of the tumours because breast cancers by nature are geographically, 
aetiologically, biologically and clinically diverse (Lerebours and Lidereau, 2002). The cancer 
stem cell theory of cancer development has implications for cancer treatment and any 
compound with the ability to target CSC and either kill them or force them to differentiate has 
the theoretical capacity to effectively treat cancer, however there are no such treatments yet in 
existence. Research into drugs that target CSC has become one of the focuses of cancer 
research and drug discovery and it is possible to selectively target this population, as has been 
shown by one study in which the proliferation and colony forming ability of breast cancer 
cells expressing the CD44+CD24- phenotype in the MCF7 cell line are preferentially inhibited 
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by three NF-κB pathway inhibitors, namely parthenolide, pyrrolidinedithiocarbamate and its 
analog diethyldithiocarbamate (Zhou et al., 2008). Another study showed that BRCA1 breast 
cancers become more sensitised to current chemotherapy drugs after treatment with 17-
DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), an Hsp90 
inhibitor (Wright et al., 2008). Another Hsp90 inhibitor, 17-AAG (17-allylamino-17-
demethoxygeldanamycin), is able to inhibit the growth of human gliomas stem cells both in 
vitro and in vivo (Sauvageot et al., 2009). As with the other properties of different breast 
cancers, it appears that the alleged cancer stem cell responsible for tumour development and 
maintenance in one type of breast cancer is not responsible for the same in a different breast 
cancer subtype (Honeth et al., 2008). The tumorigenic cells responsible for tumour initiation 
and progression have not been identified for all breast cancer subtypes and it is unknown 
whether these cells are completely different or whether they have some common 
characteristic that could be targeted.  
 
In order to design treatments that can effectively target CSC it is crucial to identify and 
understand the differences between the CSC, normal adult stem cells and normal mature cells 
and a potential way this could be done is comparing the gene and protein expression profiling 
of these cells (Zhao et al., 2008). Unfortunately, not enough is currently known about CSC 
and the mechanisms by which they survive in the tumour environment and whether they have 
any unique biological characteristics that could be exploited in the development of novel 
drugs to target the CSC (Zhao et al., 2008). Should an effective treatment targeting CSC be 
developed it may be best to use this treatment in conjunction with conventional chemotherapy 
so that both the rapidly proliferating bulk tumour cells and the slow-dividing CSC are both 
eliminated (Zhao et al., 2008). 
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1.7 Problem Statement and Knowledge Gap 
 
New therapies that are able to effectively treat cancer are always in demand as the current 
treatment strategies available often cause damage to healthy tissues, including cardiovascular, 
intestinal and respiratory tissues, and are not always successful in eradicating the tumour and 
preventing relapse (Carr et al., 2008). In addition to this, the long-term side effects of many 
currently used drugs, including trastuzumab, remain unknown (Carr et al., 2008). 
Breast cancer is the most commonly diagnosed malignancy in women, affecting an estimated 
10% of the world‟s female population and in southern Africa in particular, only 32% of 
women diagnosed with advanced breast cancer survive more than  five years (Garcia et al., 
2007). Numerous cancers, including breast cancers, are thought to arise from tumorigenic 
CSC which are believed to be responsible for the initiation and maintenance of tumours. 
These cells are biologically distinct from the bulk tumour cells and are capable of self-
renewal and asymmetric differentiation, a property they share with normal stem cells. CSC 
are also resistant to chemotherapy and therefore may repopulate the tumour after treatment 
with conventional chemotherapy drugs, leading to relapse. CSC are also believed to be 
responsible for metastasis, the most common cause of mortality in cancer patients. In the case 
of breast cancer, CSC are believed to be CD44+CD24- (Al-Hajj et al., 2003), express the 
ABCG2 drug transporter and have been shown to be chemoresistant (Li et al., 2008). There is 
also no standardized treatment for breast cancer metastases, the leading cause of death in 
breast cancer patients (Freudenberg et al., 2009; Gralow, 2005). A therapy able to 
successfully target CSC, either by forcing them to differentiate or by forcing them to undergo 
apoptosis, has the theoretical potential to effectively treat cancer if used in conjunction with 
conventional chemotherapy treatments. If CSC are indeed responsible for metastasis and a 
treatment targeting CSC is developed, successful standardized treatment of metastases may be 
achievable. Unfortunately, no treatments that specifically target CSC have yet been 
developed. This does, however, pave the way for new research into novel compounds that 
target CSC.  
 
The compounds used in this study are of marine origin and were isolated from the red algae 
Plocamium corallorhiza and Plocamium cornutum and the brown alga Sargassum 
heterophyllum, all found off the Eastern coast of South Africa. The compounds isolated from 
the Plocamium species were halogenated monoterpenes, containing either chlorine or bromine 
or both, but not nitrogen, and are much simpler organic compounds than those of currently 
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used chemotherapy drugs. These compounds have also been shown to have cytotoxic effects 
in the human oesophageal cancer cell line WHCO1 (Knott et al., 2005; Mann et al., 2007). 
The compound isolated from Sargassum heterophyllum, a tetraprenylquinone known as 
sargaquinoic acid, contains a ring structure and is more complex than the halogenated 
monoterpenes but is less complex than conventional chemotherapy drugs. It was not tested for 
cytotoxicity in WHCO1 cells but it is known to promote neurite growth and has been shown 
to induce apoptosis in human keratinocyte cell line HaCaT (Hur et al., 2008; Kamei and 
Tsang, 2003).  
 
1.8 Hypothesis 
 
Novel indigenous compounds of marine origin isolated from Plocamium species and 
Sargassum heterophyllum will have anti-breast cancer activity and anti-breast cancer stem cell 
activity. 
 
1.9 Objectives 
 
The broad objective of this investigation was to screen novel indigenous algal compounds for 
toxicity against breast cancer cells and breast CSC. Using novel small molecules, namely 
marine compounds isolated from red and brown algae, most already shown to have anti-
cancer activity in human oesophageal cancer cell line WHCO1, the specific objectives of this 
study were to: 
 
1. Screen the indigenous algal compounds for cytotoxicity in breast epithelial cell line 
MCF12A and breast epithelial cancer cell line MCF7 and determine the concentration 
at which 50% growth inhibition occurs (IC50) values of the compounds in both cell 
lines   
2. Identify the cancer stem cell-containing side population in breast cancer epithelial cell 
line MCF7 and determine the cytotoxic effect of selected algal compounds on the side 
population in this cell line 
3. Perform a preliminary investigation into the apoptosis-inducing ability of selected 
indigenous algal compounds in MCF7 epithelial breast cancer cells 
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2 MATERIALS AND METHODS 
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2.1 Novel Indigenous Algal Compounds Isolated from 
Indigenous Red and Brown Algae 
The compounds used for cytotoxicity testing on cell lines are shown in Table 1. The 
compounds are halogenated monoterpenes isolated from Plocamium sea sponges off the 
Eastern Cape coast in South Africa. The exception is RUMB-010, a tetraprenylquinone 
isolated from Sargassum heterophyllum (Knott et al., 2005; Mann et al., 2007). The structures 
of all compounds were verified by nuclear magnetic resonance (NMR). All compounds were 
initially dissolved in dimethyl sulfoxide (DMSO) (Sigma) before dilution to working 
concentrations in cell culture media. 
 
2.2 Cell Culture 
The cell lines used for cytotoxicity testing were the MCF12A and MCF7 cell lines (both from 
ATCC). The MCF12A cell line is a breast epithelial cell line that underwent spontaneous 
immortalisation and was derived from a 60 year old Caucasian adult female (Paine et al., 
1992; Pauley, 1993). The MCF7 cell line is a breast epithelial adenocarcinoma cell line 
derived from a metastatic pleural effusion in a 69 year old Caucasian adult female (Soule et 
al., 1973). MCF12A cells were cultured using a 1:1 ratio of Ham‟s F10 (Sigma Aldrich) and 
DMEM supplemented with 5% Foetal Calf Serum (FCS) (PAA Laboratories), 100 U.ml-1 
penicillin-streptomycin (BioWhittaker), 20 ng.ml-1 epidermal growth factor, 100 ng.ml-1 
cholera toxin, 500 ng.ml-1 hydrocortisone and 10 µg.ml-1 insulin. MCF7 cells were routinely 
cultured in Dulbecco‟s Modified Eagle Medium (DMEM) (Gibco) supplemented with 5% 
heat inactivated FCS, 100 U.ml-1 penicillin-streptomycin and 2 mM L-glutamine.  Cells were 
subcultured at a ratio of 1:2 every 3 to 4 days by aspirating the media from the flask, washing 
the cells with sterile 1 × PBS warmed to 37°C (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4.2H2O, 1.47 mM KH2PO4, pH 7.4), adding 1 ml 1 × Trypsin/EDTA 
(ethylenediaminetetraacetic acid) (porcine trypsin with 0.2 g.l-1 EDTA) and incubating the 
cells at 37°C and 5% CO2 (carbon dioxide) until the cells lifted. The trypsinisation was 
stopped by the addition of serum-containing media, and cells collected by centrifugation at 
800g. The media supernatant was discarded and the cells resuspended in 20 ml media warmed 
to 37°C and 10 ml each transferred to T75 culture flasks (Corning). 
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Table 1: The code, name, structure, molecular mass and source of the compounds used 
in the anti-cancer and anti-cancer stem cell analyses 
 
 
Code Name Structure Mass Sourre (g.mar', 
RUMB- Plocoralide ~ ~ 364.93 Plocamium 
001 A ~aD' cora/Iorhiza 
, , 
RUMB- Plocoralide H,c a ~ 399.38 Plocamium 
002 B B, 
'" 
corallorhiza 
'" , , 
RUMB- Plocoralide H3C CI CH:. 346.94 Plocamium 
003 C C~CHa, cora/Iorhiza 
CI a 
RUMB- Plocoralide H,c a H,c a 354.96 Plocamium 
004 0 Br~a cora/Iorhiza 
a 
RUMB- Plocoralide H,c a H,c a 443.83 Plocamium 
005 E Br~ cora/Iorhiza B, 
B, 
RUMB- Plocoral A ~ ~ 310.03 Plocamium 
007 ~aD cora/Iorhiza 
, , 
RUMB- Plocoral B H:.C a ata 300.02 Plocamium 
008 B'~aD cora/Iorhiza 
RUMB- Sargaquinoic r - , 424.58 Sargassum 
- -010 acid 
- 7 7 7 heterophyllum 
I I 
-,. 
RUMB- Plocornulide a a 308.46 Plocamium 
015 A it", cornutum ,y 
'" 
RUMB- Plocornulide ~ 284.02 Plocamium 017/018 C-erythro cornutum , a 
Plocornulide CII:J H]C a 
C- threo ~ 
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2.3 Cytotoxicity Assays 
 
The cytotoxicity of the compounds (Table 1) in MCF12A and MCF7 cells was determined 
using the Cell Proliferation Kit I (MTT) (Roche) according to the manufacturers‟ instructions. 
The assay is based on the reduction of the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to purple formazan crystals in metabolically active cells 
(Berridge and Tan, 1993). A 100 µl volume of 6 ×103 cells.ml-1 cell suspension (6000 cells) 
was added to each well in 96 well plates (Nunc) and incubated overnight at 37°C and 5% 
CO2. The optimum treatment time was determined by conducting MTT assays on MCF7 cells 
after treatment with paclitaxel at concentrations ranging from 0.01 µM to 5 µM after 24 
hours, 48 hours, 72 hours and 96 hours. Thereafter, MCF7 cells were treated with the 
differing concentrations of compounds and controls as indicated in figure legends and 
incubated for 96 hours at 37°C and 5% CO2. The assay was validated using MCF12A and 
MCF7 cells treated with paclitaxel at concentrations ranging from 0.01 µM to 0.15 µM 
included on each 96-well plate and assayed in the same way as the cells treated with the algal 
compounds. The cytotoxicity testing for individual compounds was performed in triplicate, 
with each concentration of that compound tested in quadruplicate. After treatment with the 
compounds the cells were observed under the microscope to determine qualitatively whether 
the compounds had any cytotoxic effect on the cells. A 5 µl volume of MTT reagent was 
added to each well and incubated for 4 hours at 37°C and 5% CO2, following which 100 µl of 
solubilisation solution was added to each well and incubated overnight at 37°C and 5% CO2. 
The colour change from yellow to purple was measured by quantifying the absorbance of 
each well at 550 nm using a PowerWave spectrophotometer (BioTek). The average 
absorbance of each compound at each different concentration was calculated and the cells 
treated with 0.25% DMSO were regarded as having 100% cell survival. The average 
percentage survival of each compound at each concentration on each 96 well plate was 
calculated using the 100% survival of the DMSO-treated cells as a reference. The percentage 
survival of the cell lines at the different concentrations of each compound was plotted on a 
graph from which the IC50 values (the concentration at which 50% growth inhibition is 
reached) for each compound were calculated. Student‟s t-test (two-tailed, two sample with 
equal variance) was conducted to determine whether the difference in IC50 values of each 
compound in the MCF7 cell line was statistically significant when compared with the IC50 
values in the MCF12A cell line. All error bars on the graphs from which the IC50 values were 
calculated represent the standard deviation of the relevant results. 
 
Jessica C Lawson 2010 
37 
 
 
Figure 2: Reduction of MTT by metabolically active cells 
Reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to formazan by NADH, as 
happens in metabolically active cells (adapted from (Berridge and Tan, 1993). 
 
 
2.4 Putative cancer stem cell /Side Population Analyses 
 
2.4.1 Flow Cytometry Based on Exclusion of Hoechst 33342  
The presence of the side population in MCF7 cells was first confirmed by treating MCF7 cells 
as follows: MCF7 cells were counted manually using a haemocytometer and resuspended in 
media to a concentration of 1 × 104 cells.ml-1. A 1 ml volume of the cell suspension was 
added to each of two T75 culture flasks and a further 9 ml of media was added to each flask. 
The MCF7 cells were incubated at 37°C and 5% CO2 for 48 hours, when the cells had formed 
a confluent layer. One flask was washed with 1 × PBS (pH 7.4) warmed to 37°C and then 
incubated at 37°C for 10 minutes in serum-containing media with 5 µg.ml-1 reserpine 
(Sigma), an ABCG2 inhibitor. Both flasks were washed with serum-containing media 
warmed to 37°C and incubated in at 37°C for 2 hours in serum-containing media with 5 
µg.ml-1 Hoechst 33342, with sporadic agitation. The media was removed, the cells washed 
twice with cold 1 × PBS (pH 7.4) and then harvested by trypsinisation. The cells were 
collected by centrifugation at 800g and 4°C and kept on ice in the dark until flow cytometric 
analysis. 
 
To determine the cytotoxic effect of selected algal compounds on the MCF7 side population, 
MCF7 cells were counted using a haemocytometer and resuspended in media to a 
concentration of 1 × 105 cells.ml-1. A 1 ml volume of this cell suspension was seeded into 
each well of a 12-well culture plate and the cells were incubated at 37°C and 5% CO2 for 24 
hours before treatment. The MCF7 cells were then treated for 96 hours with 1 ml solutions of 
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0.25% DMSO and 100 nM paclitaxel, RUMB-007, RUMB-008, RUMB-010 and RUMB-015 
at their IC50 values as determined by the cytotoxicity assays. The media was not replenished 
during this 96 hours (discussed in section 4.2.1). The cells were incubated with 5 µg.ml-1 
Hoechst 33342 as follows. Cells were incubated in media containing Hoechst 33342 as 
adherent cultures in the original culture flasks for 2 hours at 37°C with sporadic agitation. The 
cells were harvested by trypsinisation, washed twice with cold 1 × PBS (pH 7.4) and collected 
by centrifugation at 800g and 4°C and kept on ice in the dark until flow cytometric analysis. 
Cells were sorted based on the presence or absence of Hoechst 33342 using a FACSVantage 
SE flow cytometer (BD Biosciences) equipped with a Coherent Innova 300C water-cooled 
laser (BD Biosciences). The Hoechst 33342 dye was excited at 350 nm and dual fluorescence 
emission measured at 450 nm in flow channel 1 (FL-1) (Hoechst Blue) and 675 nm in flow 
channel 3 (FL-3) (Hoechst Red). All error bars on the graphs depicting the Hoechst 33342-
excluding cells represent the standard deviation of the relevant results. 
 
2.4.2 Flow Cytometry Based on ABCG2 Staining 
MCF7 cells were counted manually using a haemocytometer and resuspended to give a cell 
concentration of 1 × 106 cells.ml-1. A 1 ml volume (1 × 106 cells) of cells was seeded into each 
well of 3 6-well plates and another 1 ml of culture media was added to each well. The cells 
were incubated at 37°C and 5% CO2 for 24 hours before treatment. The cells were then 
treated with 0.25% DMSO, 10 nM paclitaxel and selected compounds at a concentrations 
higher than their IC50 values determined from the results of the MTT cytotoxicity analyses 
(Section 2.3 and Chapter 3, Figure 15.). All samples were incubated at 37°C and 5% CO2 for 
96 hours, following which they were harvested and washed with cold 1 × PBS (pH 7.4). Each 
sample was then incubated with 1 µg biotinylated anti-human CD338 (ABCG2) (BioLegend) 
in cold  1 × PBS (pH 7.4) for 1 hour at 4°C following which the cells were washed with ice 
cold 1 × PBS (pH 7.4). The cells were then incubated in 2 µg streptavidin-FITC (Sigma) at 
4°C in the dark for 30 minutes, washed with ice cold 1 × PBS (pH 7.4), resuspended in 100 µl 
ice cold 1 × PBS (pH 7.4) with 1 µg.ml-1 propidium iodide (Fluka) and analysed by flow 
cytometry using the Beckman Coulter FC 500 flow cytometer. The FITC was excited at 488 
nm and its fluorescence measured at 530 nm in flow channel 1 (FL-1). 
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2.5  Apoptosis Assays 
 
2.5.1 PARP detection using Western blot analysis 
MCF7 cells were counted manually using a haemocytometer and resuspended to give a cell 
concentration of 2 × 105 cells.ml-1. A 500 µl volume (1 × 105 cells) of cells was seeded into 
each well of 2 24-well plates and the cells were incubated at 37°C and 5% CO2 for 24 hours 
before treatment. The MCF7 cells (1 × 105) were treated with 0.25% DMSO, serum 
starvation, 100 nM hydrogen peroxide (H2O2), 100 nM paclitaxel and the selected novel 
indigenous algal compounds at the IC50 values as determined by the cytotoxicity assays for 24 
hours at 37°C and 5% CO2. The cells were harvested in 50 µl SDS (sodium dodecyl sulphate) 
loading buffer (125mM Tris-HCl pH 6.8, 2% SDS, 20% glycerol, 0.2% bromophenol blue) 
and boiled for 5 minutes. A 20 µl volume of each sample (40 000 cells) was loaded into each 
well of an SDS gel with a 12% SDS resolving gel and 4% stacking gel (Appendix 1). The 
proteins were resolved at 150 V and visualized by staining the gels with Coomassie staining 
solution (40% methanol; 10% acetic acid; 50% water; 0.1 % (w/v) Coomassie Brilliant Blue 
R250) and destain solution (40% methanol; 10% acetic acid; 50% water). The proteins on the 
gels were transferred from the SDS gels to Western nitrocellulose membranes (BioRad) in 
Western transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 100 V for 1 hour. 
The membranes were incubated at 4°C in 5% (w/v) milk block in Tris-buffered saline-Tween 
(TBST) (50 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.5) for 1 hour following which 
they were incubated in a 1 in 500 dilution of purified mouse anti-human PARP (poly (ADP-
ribose) polymerase)  (BD Pharmingen) in 5% (w/v) milk block in TBST (pH 7.6) at 4°C 
overnight with shaking. The membranes were washed four times for 15 minutes each with 
TBST to remove the primary antibody following which they were incubated in a 1 in 2000 
dilution of goat anti-mouse HRP in 5% milk block for 1 hour at 4°C with shaking. The 
membranes were washed with TBST as before. The presence of PARP on the membranes was 
visualized using the ECL Advance Western Blotting Kit (GE Healthcare). Images were 
recorded using the Molecular Imager ChemiDoc XRS System (BioRad).   
 
2.5.2 Immunofluorescent detection of apoptosis 
To investigate the ability of selected compounds to induce apoptosis, MCF7 cells were 
counted manually using a haemocytometer and resuspended to give a cell concentration of 1 × 
105 cells.ml-1. A 200 µl volume (2 × 104 cells) of cells was seeded into each chamber of an 8-
chamber microscope slide and the cells were incubated at 37°C and 5% CO2 for 24 hours 
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before treatment. Treatments included 0.25% DMSO, 100 nM paclitaxel and RUMB-001, 
RUMB-002, RUMB-007, RUMB-010, RUMB-015 and RUMB-017/018 at the IC50 values as 
determined by the cytotoxicity assays (Section 2.3 and Chapter 3, Figure 15.) for 48 hours. 
The cells were washed with 1× PBS (pH 7.4) and then treated with 10 µg.ml-1 nuclear stain 
Hoechst 33342 at room temperature in the dark for 10 minutes. The cells were then washed 
with 1× PBS (pH 7.4) again and the coverslip mounted on the slide using fluorescent 
mounting medium (Dako). The cells were visualized using a Zeiss LSM META 510 confocal 
laser scanning microscope. A total of 150 cells from each sample were counted from at least 
three randomly selected fields of view. The number of apoptotic cells present in each sample 
of 150 cells was recorded and the percentage of apoptotic cells in each sample calculated. 
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3 DETERMINATION OF CYTOTOXICITY OF MARINE 
COMPOUNDS IN MCF12A AND MCF7 CELLS 
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3.1 Introduction 
 When searching for novel drugs or compounds to target cancer cells, the level of cytotoxicity 
of the compounds in both the target cells and other normal cells that may be adversely 
affected should be determined  (Balis, 2002). Should a compound exhibit a high level of 
cytotoxicity in the target cells but also in other non-target or normal cells, the compound may 
not be effective as a drug. One of the main problems facing chemotherapy has been the 
toxicity of chemotherapeutic drugs to normal cells. When investigating potential novel 
chemotherapeutic drugs, therefore, the difference in dose response between the normal and 
cancer cells is vital. An ideal chemotherapeutic drug is one which has a high, specific 
cytotoxicity to the target cells, in this case the cancer cells, while having little or no 
cytotoxicity in normal cells (DeVita and Chu, 2008).  
 
Monoterpenes have already been used in the treatment of cancer (Gould, 1997; Myers, 1997). 
With respect to breast cancer, some of these monoterpenes act by interfering with signal 
transduction pathways, thereby changing gene expression and resulting in tumour regression 
(Gould, 1997). Some monoterpenes have been patented as potential chemotherapeutic drugs 
and in addition to having anti-cancer activity these compounds are also capable of sensitising 
select tumours to radiation (Myers, 1997). Marine organisms are known to be a source of 
chemically and biologically varied compounds, many of which might prove to be effective 
anti-cancer agents (Valeriote et al., 1994). Among some compounds isolated from marine 
organisms that have shown anti-cancer activity are didemnin B from Trididemnum solidum 
(Mittelman et al., 1999; Rinehart et al., 1988; Taylor et al., 1992) and bryostatin from Bugula 
neritina (Hornung et al., 1992; Kerr et al., 1996). Some marine halogenated monoterpenes 
have been demonstrated as having anti-cancer activity, some as far back as in 1992 (Fuller et 
al., 1992; Polzin et al., 2003). A halogenated monoterpene, isolated from Portieria 
hornemannii, containing both bromine and chlorine groups was shown to have high levels of 
cytotoxicity against brain, colon and kidney tumours (Fuller et al., 1992). In another study, 
four halogenated monoterpenes from Plocamium cartilagineum showed anti-cancer activity 
against colon adenocarcinoma cell line SW480 and cervical adenocarcinoma cell line HeLa 
but showed no toxic effects against non-cancerous Chinese hamster ovary cell line (de Ines et 
al., 2004). Nine halogenated monoterpenes isolated from the red alga Plocamium corallorhiza 
and Plocamium cornutum and one tetraprenylquinone isolated from the brown algae 
Sargassum heterophyllum, all collected off the eastern coast of South Africa, were 
investigated for their cytotoxicity towards MCF12A and MCF7 cell lines. 
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The MCF12A cell line represents „normal‟ cells while the MCF7 cell line represents cancer 
cells. These compounds were selected for cytotoxicity analyses in MCF12A and MCF7 cell 
lines because some of them have been shown to exhibit moderate cytotoxic activity towards 
the WHCO1 human oesophageal cancer cell line and have IC50 values in these cells of 
between 10 µM and 90 µM (Knott et al., 2005; Mann et al., 2007). The IC50 value of a 
compound, or the concentration at which 50% cell death occurs, is commonly used as a 
measure of cytotoxicity in cells. The aim of the cytotoxicity assays was to select compounds 
with a more pronounced cytotoxic effect in the MCF7 cell line than in the MCF12A cell line 
for further analysis and the difference between the IC50 values calculated for the different 
compounds in each cell line would ideally be statistically significant as determined by 
Student‟s t-test. Four compounds that had IC50 values at least three times higher in MCF12A 
cells than in MCF7 cells were selected so that treatment at a concentration toxic to the cancer 
cells would have little effect on normal cells. A further two compounds were selected, one 
which displayed high cytotoxicity in both cell lines and one which was not cytotoxic to either 
cell line. 
 
3.2 Results and Discussion 
Before determining the effect of the algal compounds in MCF12A and MCF7 cells it was 
necessary to define what was meant by the term „cytotoxicity‟ in the context of this study. The 
MTT assay is commonly used as a measure of cytotoxicity through the identification of 
metabolically active cells (Berridge and Tan, 1993). While all dead cells will indeed be 
metabolically inactive, not all metabolically inactive cells will necessarily be dead. Rather 
these cells may have entered replicative cell senescence (Matsumura et al., 1979; Shay and 
Wright, 2000). This is a potential limitation of the MTT assay, which measures cell 
proliferation on the basis of metabolism and therefore may not discriminate between dead and 
senescent cells. For the purpose of this study, the term „cytotoxicity‟ will be used to describe 
the lack of proliferation or the inhibition of proliferation of the cells as measured by the MTT 
assay. The IC50 values calculated for the algal compounds in the different cell lines is 
therefore representative of the concentration at which 50% growth inhibition, regardless of 
whether it is a result of death or cellular senescence, is reached. The cytotoxicity of each 
compound in both MCF12A and MCF7 cell lines was determined using the MTT assay 
method in which MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is 
reduced to formazan crystals by NADH and NADPH in metabolically active cells (Figure 2) 
(Berridge and Tan, 1993). This change was then measured spectrophotometrically at 550 nm.  
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3.2.1 Optimisation and validation of MTT assay on MCF12A and MCF7 
cells using Paclitaxel 
The first step in the analysis of the cytotoxicity of the algal compounds was the determination 
of the optimal time for which cells should be treated with the algal compounds and this was 
done using MCF7 cells treated with a range of concentrations of the existing 
chemotherapeutic agent, paclitaxel. The MCF7 cells (6000) were treated with between 0.01 
µM and 5 µM paclitaxel for 24 hours, 48 hours, 72 hours and 96 hours before cell survival 
was measured using the MTT assay ( 
Figure 3 3). The most pronounced dose response was observed after treatment of the MCF7 
cells with paclitaxel for 96 hours. It was decided that all subsequent MTT assays in which the 
cytotoxic effect of the algal compounds were investigated in MCF12A and MCF7 cells would 
be conducted after the cells were treated with differing concentrations of the algal compounds 
for 96 hours, even though a similar dose response was seen after treatment of the MCF7 cells 
with paclitaxel for 72 hours. 
 
MCF12A and MCF7 cells (6000 cells) were treated with between 0.5 µM and 100 µM of each 
compound for 96 hours, following which the anti-proliferative activity of the compounds was 
measured. This concentration range was chosen as it would allow observation of a cytotoxic 
effect in both the nanomolar range and the micromolar range, following which the 
concentration range could be narrowed if necessary. The effect of each compound on the cells 
lines was represented graphically as a function of concentration (on the x-axis) versus percent 
survival (on the y-axis). The DMSO-treated cells were taken as 100% survival, and the 
percent survival of the cells after treatment with each compound tested could then be 
calculated relative to the DMSO control. From these representations the concentration of each 
compound at which 50% growth inhibition (IC50) is reached can be calculated from a linear 
trendline fitted to the graph using the straight line equation y = mx + c. Paclitaxel was used as 
a positive control for cytotoxicity and has a known IC50 in MCF7s of approximately 100 nM 
but the IC50 in MCF12As is unknown. 
 
The results of the MTT assays carried out on MCF12A and MCF7 cells after treatment with 
varying concentrations of paclitaxel (between 0.01 µM and 0.15 µM) for 96 hours are shown 
in Figure 4. After conducting the MTT assay on the MCF7 cells treated with between 0.01 
µM and 5 µM to determine the optimum treatment time it was observed that treatment with 
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0.5 µM and 5 µM elicited the same cytotoxic response at each time point. The concentration 
range of paclitaxel used in subsequent assays in which the cytotoxicity of the algal 
compounds was tested was therefore changed to between 0.01 µM and 0.15 µM in order to 
obtain a linear dose response. 
Figure 4 shows the results of the validation of the cytotoxicity tests for MCF12A (Figure 4A) 
and MCF7 (Figure 4B) cells when treated with different concentrations of paclitaxel, a 
comparison of the cell survival in MCF12A and MCF7 cells (Figure 4) and the structure of 
paclitaxel and the calculated IC50 values in both cell lines (Figure 4D). The IC50 values of 
paclitaxel in MCF12A and MCF7 cells were calculated to be 5.36 nM and 88.7 nM 
respectively (Figure 4). No published data could be found regarding the IC50 of paclitaxel in 
MCF12A cells but from these results the IC50 was calculated to be 5.36 nM. The published 
IC50 of paclitaxel in MCF7 cells is approximately 100 nM (Dwight et al., 1997), close to the 
calculated IC50 of 88.7 nM obtained from these data, thereby validating the MTT assay being 
used. The calculated IC50 of paclitaxel in MCF12A cells was 5.36 µM but no published value 
for this could be found. The difference in the IC50 values in MCF12A and MCF7 cells was 
found to be statistically significant using Student‟s t-test (p < 0.03). Closer observation of the 
shape of the curve of Figure 4A suggests that the calculated IC50 value for paclitaxel in 
MCF12A cells may be higher than the actual value. The anti-proliferative effect of the 
paclitaxel on the MCF12A cells was already at its highest after treatment of the cells at 0.01 
µM, the lowest concentration point. As such, calculation of the IC50 of paclitaxel in MCF12A 
cells from the curves shown in Figure 4A may not be accurate. To accurately determine the 
IC50 of paclitaxel in MCF12A cells it would be necessary to repeat the assay using 
concentrations of paclitaxel within the linear range (0 – 0.01uM). 
 
3.2.2 Determination of the IC50 values of algal compounds in MCF12A 
and MCF7 cells 
The cytotoxic effects of the indigenous algal compounds were investigated in MCF12A and 
MCF7 cells using the MTT assay and concentrations of between 0.5 µM and 100 µM. This 
concentration range was chosen as it would allow the observation of a cytotoxic effect over a 
wide concentration range, from the low (0.5 µM) to the high micromolar range (100 µM). In 
addition to this the IC50 values of these compounds in WHCO1 oesophageal cancer cells 
ranges from 7.5 µM to 88 µM (Knott et al., 2005; Mann et al., 2007). The concentration range 
selected for compound testing in MCF12A and MCF7 cells would allow for any effect on the 
cells in the same range as seen in WHCO1 cells to be observed but would also allow for 
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effects below and above this range to be seen. The data are presented for individual 
compounds as dose response curves showing the percent survival of MCF12A and MCF7 
cells at each concentration of the different compounds in triplicate. Also shown is a dose 
response curve showing the average percentage survival both cell lines at the different 
compound concentrations as well as the structure of each compound and the calculated IC50 
values for the particular compound. To determine whether the difference in the IC50 values 
calculated for the different compounds in each cell line was statistically significant two-tailed 
two-sample equal variance Student‟s t-tests were conducted. The cytotoxic effect of each 
novel compound was investigated using the validated MTT assay by treating the MCF12A 
and MCF7 cell lines with five different concentrations (including 0 µM) of each compound. 
Each concentration was repeated in quadruplicate on a 96 well plate and each plate was 
repeated in triplicate. Not all the compounds tested resulted in 50% cell death and so the 
calculation of the IC50 values for these compounds relies on the extrapolation of the data 
beyond the concentration range tested. Unfortunately, data extrapolation may result in 
inaccurate calculations and the IC50 values calculated for all compounds tested in both 
MCF12A and MCF7 cells in which 50% cell death was not observed may be an 
underestimation. In order to obtain a more accurate IC50 value for those compounds, a further 
experiment in which the concentration range of the compounds tested is expanded would be 
required. 
 
3.2.2.1 RUMB-001 
RUMB-001, also called Plocoralide A, is a polyhalogenated monoterpene containing both 
chlorine and bromine isolated from Plocamium corallorhiza. The results obtained from the 
MTT assays on MCF12A and MCF7 cell lines after treatment with RUMB-001 are shown in 
Figure 5. A dose response was observed in both the MCF12A (Figure 5A) and MCF7 (Figure 
5B) cells. The dose response in the MCF7 cells appeared to be more pronounced than that 
observed in the MCF12A cells, as is shown in Figure 5C. The IC50 values of RUMB-001 in 
MCF12A and MCF7 cell lines were calculated to be 164.3 µM and 58.1 µM respectively, a 
difference was calculated to be statistically significant (p<0.05) using Student‟s t-test. 
RUMB-001 is almost three times more toxic in MCF7 cells than in MCF12A cells. There was 
a standard deviation of 69 µM observed when calculating the IC50 of RUMB-001 in MCF12A 
cells which is a large margin of error considering the calculated IC50 value of this compound 
in the MCF12A cells was 164.3 µM. In addition, the calculated IC50 of RUMB-001 in 
MCF12A cells is higher than the highest concentration of the compound tested. The IC50 of 
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this compound in MCF12A cells may well be an underestimation and so can be said to be 
greater than 164.3 µM (IC50 > 164.3 µM). 
 
3.2.2.2 RUMB-002 
Figure 6 shows the results from the MTT assays after treatment of MCF12A and MCF7 cells 
with RUMB-002, a chlorinated and brominated monoterpene also called Plocoralide B 
isolated from Plocamium corallorhiza. There is a clear dose response seen in the MCF7 cells 
treated with RUMB-002 (Figure 6B). A lesser dose response was seen in the MCF12A cells 
(Figure 6A) than in the MCF7 cells which is shown in Figure 6C. The IC50 of RUMB-002 in 
MCF12A and MCF7 cells was calculated to be 238.3 µM and 65.1 µM respectively and this 
difference was statistically significant (p<0.05). As with RUMB-001, the IC50 of RUMB-002 
is approximately three times lower in MCF7 cells than in MCF12A cells, meaning that this 
molecule is three times more toxic to the MCF7 cancer cells than the MCF12A breast 
epithelial cells, using this assay. In addition, the IC50 of RUMB-002 in MCF12A cells is 
higher than the highest concentration of the compound tested and so the calculated IC50 may 
be an underestimation. As such, the IC50 of RUMB-002 in MCF12A cells can be said to be 
greater than 238.3 µM (IC50 > 238.3 µM). 
 
3.2.2.3 RUMB-003 
RUMB-003, also called Plocoralide C, is a polychlorinated monoterpene isolated from 
Plocamium corallorhiza. The results from the cytotoxicity analyses obtained using the MTT 
assay on MCF12A and MCF7 cells after treatment with this compound are shown in Figure 7. 
A slight dose response was observed in MCF12A cells (Figure 7A) and a more marked dose 
response was seen in the MCF7 cells (Figure 7B). The IC50 values of RUMB-003 were 
calculated to be 184.7 µM and 90.0 µM in MCF12A and MCF7 cells respectively. The 
difference between the IC50 values of this compound in the two cell lines was calculated to be 
significantly different (p<0.05). As with RUMB-001 and RUMB-002, the IC50 of RUMB-003 
in MCF12A cells is higher than 100 µM, the highest compound concentration tested. The IC50 
of RUMB-003 may therefore be higher than 184.7 µM (IC50 > 184.7 µM). 
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3.2.2.4 RUMB-004 
The results from the MTT assay carried out after treatment of MCF7 and MCF12A cells with 
RUMB-004 is shown in Figure 8. RUMB-004, or Plocoralide D, is a polyhalogenated 
monoterpene isolated from Plocamium corallorhiza and contains both chlorine and bromine. 
The IC50 of RUMB-004 in MCF12A cells was calculated even though it appears to have little 
effect on the cells with no distinct dose response observed (Figure 8A). A more distinct dose 
response was observed in the MCF7 cells treated with RUMB-004 (Figure 8). The 
concentrations of RUMB-004 which results in 50% growth inhibition in MCF12A and MCF7 
cells are 225 µM and 90.0 µM respectively, a difference that was confirmed as being 
significant using Student‟s t-test (p<0.05). Also, in spite of the fact that RUMB-004 is more 
cytotoxic in the MCF7 cancer cells than the MCF12A cells, the concentration required to 
achieve 50% cell death in the cancer cells was still observed to be much higher than desired 
for a potential hit compound as treatment of the MCF12A cells with 90.0 µM of the 
compound may induce a dose response. As a result of the IC50 of RUMB-004 in MCF12A 
cells being higher than the highest compound concentration tested and the necessary use of 
data extrapolation to calculate this IC50, the IC50 of this compound in MCF12A cells can be 
said to be greater than the 225 µM it was calculated to be (IC50 > 225 µM). 
 
3.2.2.5 RUMB-005 
RUMB-005, also known as Plocoralide E, is a polyhalogenated monoterpene, containing 
chlorine and bromine, isolated from Plocamium corallorhiza. The results from the 
cytotoxicity determination using the MTT assay after treatment of MCF12A and MCF7 cells 
with RUMB-005 is shown in Figure 9. The IC50 calculated for RUMB-005 in MCF12A cells 
was 34.8 µM and in MCF7 cells was 69.7 µM. RUMB-005 was the only compound tested 
that exhibited a significantly (p<0.05) higher level of cytotoxicity towards the normal breast 
epithelial MCF12A cells than the MCF7 breast adenocarcinoma cells and in this case the IC50 
in MCF12A cells was almost exactly half of that in MCF7 cells. 
 
3.2.2.6 RUMB-007 
RUMB-007 is a brominated monoterpene isolated from Plocamium corallorhiza and is also 
known as Plocoral A. The cytotoxicity results obtained from treating MCF12A and MCF7 
cells with RUMB-7 are shown in Figure 10. Dose responses were observed in both the 
MCF12A (Figure 10A) and MCF7 (Figure 10B) cells although the dose response in the 
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MCF7 cells was significantly higher (p<0.05) in the MCF7 cells. The IC50 values calculated 
for RUMB-007 in MCF12A and MCF7 cells were 127.6 µM and 33.0 µM respectively, 
although the standard deviation found when calculating the IC50 in MCF12A cells was 30.2 
µM.  
3.2.2.7 RUMB-008 
RUMB-008, or Plocoral B, is a chlorinated and brominated monoterpene isolated from 
Plocamium corallorhiza. The results obtained from the MTT assays on MCF12A and MCF7 
cells after treatment with RUMB-008 are shown in Figure 11. Both the MCF12A (Figure 
11A) and MCF7 (Figure 11B) showed marked dose responses as a result of treatment with 
this compound. The IC50 value calculated for RUMB-008 in MCF12A cells was 62.3 µM and 
for MCF7 cells was 28.8 µM. Even though the difference in the IC50 values of RUMB-008 in 
MCF12A and MCF7 cells was not as great as with some other compounds, the difference was 
still found to be significant (p<0.05). 
 
3.2.2.8 RUMB-010 
RUMB-010, also known as sargaquinoic acid, is a tetraprenylquinone isolated from 
Sargassum heterophyllum. The results obtained from the MTT assay carried out on MCF12A 
and MCF7 cells after treatment with RUMB-010 are shown in Figure 12. RUMB-010 was the 
only marine molecule used in this study that has not been previously tested for anti-cancer 
activity on WHCO1 oesophageal cancer cells (Knott et al., 2005; Mann et al., 2007). A dose 
response was seen in the MCF7 cells treated with RUMB-010 (Figure 12B). The IC50 of 
RUMB-010 in MCF7 cancer cells was calculated to be 68.4 µM, showing that RUMB-010 is 
cytotoxic towards these cells, albeit not at the same level as, for example, RUMB-007 and 
RUMB-008. When looking at Figure 12A, no obvious dose response in MCF12A cells treated 
with RUMB-010 was observed. The lack of dose response seen in the MCF12A cell line 
treated with RUMB-010 resulted in an inability to properly fit trendlines to the curves. As 
such the IC50 of RUMB-010 in this cell line, as well as whether the difference in the dose 
response between the two cell lines was significant, could not be calculated. In this case, the 
IC50 has been recorded as indeterminate. 
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3.2.2.9 RUMB-015 
RUMB-015 is a chlorinated monoterpene isolated from Plocamium cornutum and is 
otherwise known as Plocornulide A. The results of the cytotoxicity analyses in the MCF12A 
cell line treated with RUMB-015 are shown in Figure 13. Distinct and strong dose responses 
were seen in both the MCF12A and MCF7 cells treated with this compound. After treating the 
MCF7 cell line with concentrations of RUMB-015 ranging from 0.5 µM to 100 µM the 
concentration range was adjusted to 0.1 µM to 5 µM (Figure 13B). RUMB-015 showed high 
levels of cytotoxicity in both cell lines with calculated IC50 values of 3.5 µM and 3.0 µM in 
MCF12A and MCF7 cells respectively. The strong cytotoxic effect of RUMB-015 in both 
these cell lines can be clearly seen in Figure 13A and B where the percentage of cell survival 
drops sharply after the addition of low concentrations of RUMB-015. From Figure 13C it 
seems that the MCF12A cells (blue line) are as susceptible to RUMB-015 as MCF7 cells (red 
line) as they show decreased cell survival in comparison to the MCF7 cells. The IC50 values 
calculated for RUMB-015 in MCF12A and MCF7 cells, 3.5 µM and 3.0 µM respectively, are 
similar, as was confirmed by Student‟s t-test (p>0.05). 
 
3.2.2.10 RUMB-017/018 
RUMB-017/018, or Plocornulide C, contains both chlorine and bromine and exists as a 
mixture of enantiomers and was isolated from Plocamium cornutum. The results of the 
cytotoxicity assays carried out on MCF12A and MCF7 cells after treatment with RUMB-
017/018 are shown in Figure 14. RUMB-017/018 had little cytotoxic effect in both MCF12A 
and MCF7 cells and as shown in Figure 14A and B there is no distinct dose response 
observed after treating both cell lines with this compound. The lack of dose response 
exhibited in both cell lines is shown in Figure 14C, which shows little difference in cell 
survival between both cell lines and also shows little cell death. As such, no IC50 values for 
this compound in MCF12A and MCF7 cells could be determined. 
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Figure 3: Optimisation of the MTT assay on MCF7 cells using paclitaxel. 
Survival curve of MCF7 cells after treatment with paclitaxel at concentrations ranging from 0.01 µM to 5 µM after 24 hours (blue line), 48 hours (red line), 72 hours 
(black line) and 96 hours (purple line) as measured by the MTT assay. The percentage survival of cells was calculated by normalizing the survival of cells treated only 
with DMSO and no paclitaxel to be 100% and the survival of the cells at each concentration was calculated relative to this value. 
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Figure 4: Determination of IC50 values of paclitaxel in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with paclitaxel ranging in concentration from 0.01 µM to 0.15 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with paclitaxel at concentrations ranging 
from 0.01 µM to 0.15 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of paclitaxel and the IC50 value 
of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 5: Determination of IC50 values of RUMB-001 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-001 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-001 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-001 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 6: Determination of IC50 values of RUMB-002 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-002 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-002 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-002and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 7: Determination of IC50 values of RUMB-003 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-003 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-003 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-003and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 8: Determination of IC50 values of RUMB-004 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-004 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-004 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-004 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 9: Determination of IC50 values of RUMB-005 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-005 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-005 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-005 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 10: Determination of IC50 values of RUMB-007 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-007 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-007 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-007 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 11: Determination of IC50 values of RUMB-008 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-008 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-008 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-008 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 12: Determination of IC50 values of RUMB-010 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-010 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and blue 
lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-010 at concentrations 
ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-010 and the 
IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 13: Determination of IC50 values of RUMB-015 in MCF12A and MCF7 cells. 
A: MCF12A cells were treated with RUMB-015 ranging in concentration from 0.5 µM to 100 µM for 96 hours and B: MCF7 cells treated with RUMB-015 ranging in 
concentration from 0.1 µM to 5 µM for 96 hours (triplicates shown as black, red and blue lines). C: Comparison of the average percentage cell survival of MCF12A 
(blue line) and MCF7 (red line) cells after treatment with RUMB-015 at concentrations ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was 
calculated relative to the DMSO control (100% survival). D: Structure of RUMB-015 and the IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 
for calculations). 
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Figure 14: Determination of IC50 values of RUMB-017/018 in MCF12A and MCF7 cells. 
A: MCF12A and B: MCF7 cells were treated with RUMB-017/018 ranging in concentration from 0.5 µM to 100 µM for 96 hours (triplicates shown as black, red and 
blue lines). C: Comparison of the average percentage cell survival of MCF12A (blue line) and MCF7 (red line) cells after treatment with RUMB-017/018 at 
concentrations ranging from 0.5 µM to100 µM after 96 hours. Percentage survival was calculated relative to the DMSO control (100% survival). D: Structure of RUMB-
017/018 and the IC50 value of this compound in MCF12A and MCF7 cells (see Appendix 2 for calculations). 
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Figure 15: A comparison of the average cytotoxicity of the marine algal compounds in MCF12A (blue) and MCF7 (red) cells. 
RUMB-001, RUMB-002, RUMB-007 and RUMB-010 were selected for further studies due to their higher cytotoxicity in MCF7 cells relative to the MCF12A cells. As 
a result of their respective high and low toxicity in both MCF12A and MCF7 cells RUMB-015 and RUMB-017/018 were also included in subsequent studies. The 
average IC50 values of RUMB-010 in the MCF12A cell line and RUMB-017/018 in the MCF12A and MCF7 cell lines were indeterminate and are represented as being 
greater than 300 µM.  Each IC50 was calculated (Appendix 2) using the three cytotoxicity curves, each of which represented the average of quadruplicate samples (* 
p<0.05). 
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3.3 Comparison of toxicity in normal and cancer cell lines 
A comparison of the average IC50 values of all the marine small molecules tested on MCF12A 
and MCF7 cells using the MTT assay is shown in Figure 15. The average IC50 of each compound 
in MCF12A cells is shown in blue and the average IC50 of the compounds in MCF7 cells is 
shown in red and the standard deviations for each value are also shown. Student‟s t-test was 
conducted for all compounds on both cell lines and a statistically significant dose-dependent 
decrease in cell survival was observed in MCF12A cells for all compounds except RUMB-001, 
RUMB-004, RUMB-010 and RUMB-017/018 (p<0.05 for untreated cells as compared with cells 
treated with 100 µM of the compound). In the MCF7 cell line statistically significant dose-
dependent decreases in cell survival were observed in all compounds except RUMB-017/018 
(p<0.05 for untreated cells compared with cells treated with 100 µM of the compound). 
Compounds with differential toxicities were identified. For example compounds more toxic to the 
MCF7 cancer cells than the MCF12A cells (RUMB-001, RUMB-002, RUMB-003, RUMB-004, 
RUMB-007 and RUMB-010), a compound more toxic to the normal MCF12A cells than the 
MCF7 cells (RUMB-005), compounds toxic to both the normal and the cancer cells (RUMB-008 
and RUMB-015) and a compound non-toxic to both the MCF12A and MCF7 cells (RUMB-
017/018). The differences in the IC50 values of the compounds in MCF12A cells and MCF7 cells 
were found to be significant for RUMB-001, RUMB-002, RUMB-003, RUMB-004, RUMB-005, 
RUMB-007 and RUMB-008 (p<0.05). There was no significant difference in the IC50 values in 
MCF12A and MCF7 cells for RUMB-015 and RUMB-017/018 and the statistical significance of 
the difference in IC50 values in MCF12A and MCF7 cells for RUMB-010 could not be calculated 
as it was not possible to calculate the IC50 of this compound in MCF12A cells. The cytotoxicity 
assays in the MCF12A cell line were carried out in two consecutive stages and so the passage 
numbers of the cells used in this analysis differed by only one passage. The cellular alterations 
that occur during the continuous and extensive sub-culturing of cells, including changes in gene 
expression, cellular growth rates and morphological changes (Chang-Liu and Woloschak, 1997; 
Esquenet et al., 1997; Wenger et al., 2004), would therefore not have contributed to the variation 
observed in the results obtained in the cytotoxicity analyses carried out in the MCF12A cell line. 
The MCF12A cell line was not an ideal „normal‟ control as the in vitro growth of these cells 
required stimulation by a number of agents including cholera toxin, epidermal growth factor, 
hydrocortisone and insulin. Therefore it was not possible to determine whether the observed 
effects of the compounds in this cell line were a direct result of the compounds on the cells 
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themselves or as a result of the compound interfering or interacting with one of the stimulatory 
factors present in the culture medium. Another concern with using the MCF12A cell line is that it 
is an immortalised cell line and these cell lines are known to have altered gene expression 
profiles when compared with the primary cell lines from which they were derived (Olschlager et 
al., 2009; Sawada et al., 2005; You et al., 2004). Many immortalised cell lines show a loss of p53 
expression which often results in the cells exhibiting a higher level of chemoresistance (Bunz et 
al., 1999; Dean et al., 2005; Donehower et al., 1992; Lowe et al., 1993). The MCF12A cell line 
used may therefore have exhibited a higher level of resistance to the compounds than would have 
been observed in a primary cell line, suggesting that the compounds would have greater cytotoxic 
activity in both a primary cell line and in normal breast cells in situ. A better control cell line to 
use may be the breast epithelial cell line Hs578Bst. This cell line does not require stimulants for 
growth and is part of a paired cell line, having a tumorigenic partner cell line, Hs578T, derived 
from the same origin as the Hs578Bst cells (Hackett et al., 1977). Using these two cell lines in 
place of the MCF12A and MCF7 cells would allow the investigation of the effect of the 
compounds on a cancerous and normal cell line while eliminating any difference that may be 
observed due to different genetic backgrounds of the cells.  
 
From these results six compounds (termed priority compounds) were selected for further studies 
(Table 2). For a compound to be selected as a priority compound the IC50 in MCF7 cells had to 
be at least three times lower than in MCF12A cells and this difference should ideally be 
statistically significant. The reason for this is that any concentration used at which the compound 
would have a cytotoxic effect on the MCF7 cancer cell line there should be a minimal cytotoxic 
effect on the MCF12A normal cell line. Having said this, however, any compound that exhibited 
either high cytotoxicity or no cytotoxicity to both the MCF12A and MCF7 cell lines could also 
be of interest in future studies and in the determination of the cause of cytotoxicity or lack thereof 
in the different cells. These 6 selected compounds, shown in Table 2, will hereafter be referred to 
as priority compounds. The IC50 values calculated for paclitaxel in both MCF12A and MCF7 
cells are also shown in Table 2 and are 5.35 nM and 88.7 nM respectively. As mentioned 
previously, the IC50 of paclitaxel in MCF12A cells is unknown but in MCF7 cells has been 
reported as being 100 nM (Munster et al., 2002), close to the value of 88.7 nM calculated here. 
The results obtained from the cytotoxicity assays in the MCF12A and MCF7 cell lines show that 
paclitaxel has a greater cytotoxic effect on the MCF12A normal breast epithelial cells than on the 
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MCF7 cancer cells. Current chemotherapeutic agents are known to have adverse side effects on 
normal, healthy tissues (Carr et al., 2008) but a chemotherapy drug that exhibits a vast difference 
in cytotoxicity towards cancer and normal cells as paclitaxel does in MCF12A and MF7 cells 
raises the question as to whether this drug is actually viable as an anti-cancer agent if it is causing 
so much damage to the normal breast tissue. As discussed previously, there are various 
limitations present when using the MCF12A cell line, including the numerous stimulants the cells 
require for growth and the fact that it is an immortalised cell line. The extent to which paclitaxel 
induces cell death in the MCF12A cells may therefore not be a true reflection of the effect of 
paclitaxel on normal breast cells in situ but rather a result of the nature of the MCF12A cells. The 
IC50 values calculated for paclitaxel in the MCF12A and MCF7 cells lines are in the nanomolar 
range, whereas those calculated for the algal compounds are all in the micromolar range. While 
four of the priority compounds were selected as a result of the higher cytotoxicity exhibited in the 
MCF7 cancer cells, these compounds are not cytotoxic to the same extent. Indeed, the majority of 
chemotherapy drugs have IC50 values in the nanomolar range (Sigurdsson et al., 1986; Tian et al., 
2004; Yayoi et al., 2009). Priority compounds were selected based on their differential 
cytotoxicities in the MCF12A and MCF7 cell lines but in order to be considered as potential hit 
compounds the IC50 values in the cancer cells would have to be lowered, perhaps by alteration of 
the compounds by chemical modification (discussed in section 6.2). 
 
Four of the compounds tested, namely RUMB-001, RUMB-002, RUMB-007 and RUMB-010, 
showed three times higher cytotoxicity in the MCF7 cancer cells than in the MCF12A cells. The 
difference in the IC50 values of RUMB-001, RUMB-002 and RUMB-007 in MCF12A and MCF7 
cells were shown to be statistically significant using Student‟s t-test (p<0.05). No statistical test 
could be done on the difference in the IC50 values of RUMB-010 in MCF12A and MCF7 cells as 
the IC50 of this compound in MCF12A cells could not be calculated and is considered to be 
indeterminate. While the difference in the IC50 values of RUMB-010 in MCF12A and MCF7 
cells could not be verified as statistically significant, RUMB-010 was chosen as a priority 
compound as there is a large difference in the IC50 in MCF12A cells (IC50 > 300 µM and MCF7 
cells (IC50 = 68.4 µM). RUMB-010 is also of interest as it has a different structure to the other 
compounds in this study. Of the remaining two compounds, RUMB-015 showed high 
cytotoxicity to both the MCF12A and the MCF7 cells while RUMB-017/018 displayed little to 
no cytotoxicity in both MCF12A and MCF7 cells. The similar effects of these compounds on the 
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different cell lines were confirmed by Student‟s t-test which showed that the differences in IC50 
between MCF12A and MCF7 cells were not statistically significant (p>0.05).  
The IC50 values of RUMB-003 and RUMB-008 in MCF12A cells are double that in MCF7 cells 
and so treatment of the cancer cells at the IC50 concentrations may still elicit a cytotoxic response 
in the normal cells and as such RUMB-003 and RUMB-008 were not selected as priority 
compounds. RUMB-004, while having little cytotoxic effect in MCF12A cells still requires a 
relatively high concentration to achieve an effect in MCF7 cells and has therefore also not been 
chosen for further analyses. RUMB-005, interestingly, is the only compound tested that showed 
more cytotoxicity towards the normal MCF12A cells than the MCF7 cancer cells. This is not 
desirable in a cancer treatment, although it was observed in the treatments of MCF12A and 
MCF7 cells with paclitaxel, and so RUMB-005 was not used in subsequent experiments. This 
also suggests that the MCF12A „normal‟ control cell line used was a sub-optimal control cell 
line, most likely due to the exogenous stimulation these cells required to grow in culture. 
 
The majority of current chemotherapy drugs, including paclitaxel, doxorubicin, 17-AAG and 
geldanamycin are complex organic structures that contain multiple ring structures and nitrogen 
(Sigurdsson et al., 1986; Tian et al., 2004; Wang et al., 2006; Yayoi et al., 2009) but only one of 
the novel marine compounds tested here, namely RUMB-010, possess a ring structure and none 
of the compounds contain nitrogen. The concentration at which a drug is administered is of 
extreme importance because of the potential effects it could have on other tissues in the body as 
well as the practical issues involved with administering large amounts of a drug (Lipp and 
Bokemeyer, 1999). All the IC50 values reported here for the marine compounds are in the 
micromolar range, whereas drugs currently used in chemotherapy have IC50 values mostly in the 
nanomolar range, for example the IC50 values of paclitaxel, doxorubicin, 17-AAG and 
geldanamycin in MCF7 cells are 100 nM, 8.44 nM, 72 nM and 25 nM respectively (Munster et 
al., 2002; Yang et al., 2001; Zheng et al., 2000). The IC50 values found for the marine compounds 
tested are considerably higher than these values and while those with lower IC50 values in MCF7 
cells and higher IC50 values in MCF12A cells were selected as priority compounds (i.e. „hit‟ 
compounds), their cytotoxicity may still be too high for them to be considered lead compounds, 
though this may be made lower with rational chemical modification (discussed further later) and 
so may represent a starting point for chemical modification.  
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Table 2: Codes, names, structures and IC50 values in MCF12A and MCF7 cells of selected 
marine algal priority compounds and paclitaxel 
 
 
Code Name Structure IC50 (µM) in 
MCF12A cells 
IC50 (µM) in 
MCF7 cells 
RUMB-
001 
Plocoralide A 
CHCl2
CH3
Br Br
CH3
 
>164.3 ± 69.3 58.1 ± 4.4 
RUMB-
002 
Plocoralide B 
Br
H3C Cl
Br
CH3
CHCl2  
>238.3 ± 18.2 65.1 ± 3.0 
RUMB-
007 
Plocoral A 
CHO
CH3 CH3
Br Br  
>127.6 ± 30.2 33.0 ± 1.2 
RUMB-
010 
Sargaquinoic 
acid 
Me
Me
Me
CMe 2
CO 2H
O
O
E E E
 
Indeterminate 68.4 ± 3.4 
RUMB-
015 
Plocornulide 
A 
Cl
Cl Cl
Cl
H3C Cl
 
3.5 ± 1.1 3.0 ± 0.6 
RUMB-
017/018 
Plocornulide 
C 
Br
CH3
Cl
H3C Cl
 
Br
CH3
Cl
H3C Cl
 
Indeterminate Indeterminate 
 
Paclitaxel 
 
5.35 ±0.05 nM 88.7 ±2.9 nM 
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The reason for the difference in cytotoxicity levels between the different novel marine molecules 
tested is unclear but may be due to the electronegativity of the compounds, one of the properties 
on which the effectiveness of current chemotherapy is based (Holshouser et al., 2002; Maini et 
al., 1997; Wu et al., 2000). 
 
When looking at the selected priority compounds for example, RUMB-001 and RUMB-007 are 
almost identical, differing only in the substitution of the -CHCl2 group in RUMB-001 for -CHO 
in RUMB-007 and their IC50 values in MCF12A and MCF7 cell lines are similar. Also, RUMB-
015 is highly chlorinated which may confer increased electronegativity to this compound and 
therefore higher cytotoxicity than, for example, RUMB-017/018, which is halogenated to a lesser 
extent. RUMB-015 and RUMB-017/018 also have very similar backbones but differ vastly in 
their cytotoxicities, raising the question as to whether this is due to the difference in 
electronegativity or some other difference. Successive molecular substitution of the chlorine and 
bromine groups on these compounds with proton or methyl groups, and subsequent testing of 
these derivatives for changes in cytotoxicity, may provide information on the structure activity 
relationship (SAR) of these compounds. It should also be considered whether the existence of 
RUMB-017/018 as an enantiomer has an effect on the cytotoxic activity of the compound and 
may explain the high IC50 of this compound in both the MCF12A and MCF7 cells. It cannot be 
determined from the tests carried out here whether both enantiomers are in fact inactive, whether 
one is more cytotoxic but is masked by the other or even whether any difference in their effect on 
the cells exists. These suggestions could be determined conclusively by rational chemical 
modification of selected compounds. 
 
3.4 Conclusion 
Ten algal compounds were tested for cytotoxicity in MCF12A „normal‟ breast epithelial cells and 
MCF7 epithelial breast cancer cells from which compounds with differential cytotoxicity were 
identified. Seven compounds, namely RUMB-001, RUMB-002, RUMB-003, RUMB-004, 
RUMB-007, RUMB-008 and RUMB-010 exhibited lower cytotoxicity in MCF12A cells than in 
MCF7 cells with significant differences (p<0.05) in IC50 values of these compounds in each cell 
line except for RUMB-010 for which an IC50 in MCF12A cells could not be determined. RUMB-
005 had higher cytotoxicity in MCF12A cells when compared with MCF7 cells and the 
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difference in the IC50 values of this compound in the different cell lines was also calculated to be 
significant (p<0.05). RUMB-015 and RUMB-017/018 exhibited high and low cytotoxicity 
respectively in both cell lines. The difference in the IC50 values of RUMB-015 was not 
significant (p>0.05) but no significance could be calculated for the effect of RUMB-017/018 on 
the different cell lines as the IC50 value of RUMB-017/018 in both these cell lines was 
indeterminate. From the ten compounds tested six were selected as „priority‟ compounds based 
on their very different or similar cytotoxicities in the „normal‟ MCF12A cells and the cancerous 
MCF7 cells. In the case of RUMB-001, RUMB-002, RUMB-007 and RUMB-010 their selection 
as priority compounds was based on their IC50 value being at least three times lower in the MCF7 
cells than in the MCF12A cells. The high cytotoxicity of RUMB-015 in both MCF12A and 
MCF7 cells and the apparent lack of cytotoxicity of RUMB-017/018 in MCF12A and MCF7 
cells resulted in these two compounds also being selected as priority compounds. There is a lack 
of obvious SAR of these compounds and as such there is a need to study the cytotoxicities of 
compounds that are systematic structural derivatives of each priority compound. The priority 
compounds were then used for further cytotoxic and preliminary mechanistic studies. 
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4 DETERMINATION OF THE CYTOTOXICITY OF THE 
PRIORITY COMPOUNDS ON THE SIDE POPULATION (SP) 
IN THE MCF7 BREAST CANCER CELL LINE 
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4.1 Introduction 
The side population (SP) are small populations of cells that are enriched in undifferentiated cells 
and are also believed to be enriched for stem cells (Decraene et al., 2005; Hadnagy et al., 2006; 
Larderet et al., 2006). They have been identified in human normal tissues, including breast tissue 
(Alvi et al., 2003; Behbod et al., 2006; Dontu et al., 2003), as well as in tumours and cancer cell 
lines (Grichnik et al., 2006; Hirschmann-Jax et al., 2004; Kondo et al., 2004). These SP cells are 
known to express high levels of ABC transporters, including multi-drug resistance transporter 
ABCG2 (Zhou et al., 2001), a property that has been successfully exploited when studying the 
cancer stem cell containing-side population where Hoechst 33342 is driven out of the side 
population cells by the ABC transporters but retained in the non-side population cells (Challen 
and Little, 2006; Goodell et al., 1996). While the SP, which is thought to comprise between 0.1% 
and 2% of total tumour mass (Chuthapisith et al., 2009) has been shown to be heterogeneous, the 
characterisation of cells within the SP has shown that they are undifferentiated and tumorigenic 
with the most poorly differentiated cells being the most tumorigenic (Decraene et al., 2005; 
Hadnagy et al., 2006), suggesting the SP is the population in which the proposed CSC reside. The 
presence of the multi-drug resistant transporter on the surface of the cancer stem cell-containing 
SP cells is believed to contribute to the observed chemoresistance of these cells (Hirschmann-Jax 
et al., 2004; Li et al., 2008). There is much debate over the existence and importance of CSC, 
particularly since there is currently no accepted marker profile for identifying breast CSC, 
although many groups suggest that this population is defined by the CD44+CD24- phenotype  
(Dontu, 2008). Many of the current chemotherapy drugs target the rapidly dividing cells of the 
bulk of the tumour, leaving the CSC behind in an apparent enrichment for these cells, which are 
then able to repopulate the tumour which may lead to relapse (Dean et al., 2005). Theoretically, 
targeting the CSC would remove the source of and the cells responsible for the maintenance of 
the tumour, after which the bulk of the tumour could disintegrate or be removed using 
chemotherapy (Figure 16). Various techniques exist that allow for the investigation of toxicity of 
drugs and compounds to CSC, both in isolation and in situ. The MTT assay is commonly used to 
determine the cytotoxicity of compounds in different cell lines (Berridge and Tan, 1993) and 
should SP be successfully isolated and propagated in vitro, while maintaining their stem cell 
characteristics, it may be possible to test the toxic effects of novel compounds and potential drugs 
on CSC-containing SP using this technique. It is also possible to perform toxicity studies on CSC 
in situ. As already discussed SP the exclusion of Hoechst 33342 dye from SP cells has already 
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been used successfully in identification and isolation of the SP in various cell lines (Challen and 
Little, 2006; Decraene et al., 2005; Goodell et al., 1996; Larderet et al., 2006) and so the effect of 
novel compounds and potential drugs on the SP can be determined by treating the entire cell 
population and then investigating the changes in the proportion of Hoechst-33342 excluding or 
ABCG2+ cells by flow cytometry (Figure 16B). These techniques and others will have to be 
employed in the search to find compounds that are able to effectively target and remove CSC 
from the tumour environment. The CSC theory of cancer development proposes that CSC cause 
cancer and as a result of their inherent chemoresistance may play a large role in relapse after 
treatment. The only way to completely remove a tumour is to remove the sustaining cell 
population. The aim of this study was to investigate the cytotoxic effect of the priority 
compounds on the ABCG2+ cancer stem cell-containing side population in the MCF7 breast 
cancer cell line. 
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Figure 16: Different approaches available for the determination of toxicity to CSC 
Schematic representation of CSC isolation for toxicity studies using magnetic cell separation (A) versus in situ 
toxicity studies (B). Isolation of the SP by magnetic cell separation using a magnetically labelled SP-specific 
antibody (A) allows for toxicity studies to be carried out on the different subpopulations within a heterogeneous 
tumour or cell line. Toxicity studies can also be carried out in situ by analyzing the different cell populations present 
in a heterogeneous tumour sample or cell line after treatment (B) using, for example, flow cytometry. 
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4.2 Results and Discussion 
4.2.1 Identification of the Side Population in MCF7 cell line using Hoechst 
staining 
The CSC containing-side population cells express ABC transporter proteins, especially ABCG2, 
at high levels. As a result of the high expression levels of these transporters, the fluorescent dye 
Hoechst 33342 is actively excluded from these “side population (SP)” cells while the “non-side 
population (NSP)” cells retain the dye (Chuthapisith et al., 2009; Goodell et al., 1996). Therefore 
it is possible to distinguish between the different populations using flow cytometry. In order to 
confirm the presence of the SP in MCF7 cells one sample of MCF7 cells was incubated with 
50µM reserpine [known to inhibit the function of ABCG2 transporter (Shukla et al., 2005)] 
followed by Hoechst 33342 staining, while another sample of MCF7 cells was incubated only 
with Hoechst 33342. Both cell sets were analysed by flow cytometry using a FACSVantage SE 
flow cytometer (BD Biosciences). The Hoechst 33342 was excited at a wavelength of 350 nm 
and the fluorescence measured at 450 nm (Hoechst Blue) and 675 nm (Hoechst Red).  Reserpine 
is an ABCG2 inhibitor which removes the ability of ABCG2 to exclude Hoechst 33342 thereby 
causing the cells to retain Hoechst 33342. This was done to confirm that the SP could be 
identified using the Hoechst 33342-exclusion method and a known inhibitor of ABCG2. This was 
necessary before attempting to investigate the effect of the selected algal compounds on the SP in 
MCF7 cells so that when analysing the cells after treatment with the selected algal compounds 
the SP and any changes in the SP could be accurately identified.  
 
Figure 17A shows the dot plot of MCF7 cells stained with Hoechst 33342 only and Figure 17B 
shows the dot plot of the MCF7 cells treated with reserpine and stained with Hoechst 33342. 
Cells that exclude Hoechst 33342 would be expected to appear in the bottom left of the dot plot, 
an area representing „low‟ Hoechst 33342 staining. In a dot plot SP cells appear as a tail (Goodell 
et al., 1996). This is observed in the box enclosing the SP cells (3037 cells) in Figure 17A. If the 
SP was correctly identified in Figure 17A, treatment of the MCF7 cells with reserpine would 
result in an apparent decrease in the SP cells observed. The number of SP cells counted in the 
MCF7 cells treated with reserpine and Hoechst 33342 was 947 cells, a decrease from the 3037 
cells counted in the MCF7 cells stained with Hoechst 33342 alone. This suggests that the SP in 
MCF7 cells was correctly identified using this technique. 
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Figure 17: Confirmation of the presence of the side population in MCF7 cells using flow 
cytometry 
Flow cytometry was carried out with a FACSVantage SE flow cytometer. The Hoechst 33342 was excited at 350 nm 
and the fluorescence measured at 450 nm (Hoechst Blue) and 675 nm (Hoechst Red). A: Untreated MCF7 cells 
stained with 5 µg.ml-1 Hoechst 33342.  Cells expressing ABCG2 will be negative for Hoechst 33342 and appear in 
the bottom left quadrant of the dot plot and are represented here in the rectangular gate. There are 3037 ABCG2+ 
cells present in this gate. B: MCF7 cells treated with 50 µM reserpine and stained with 5 µg.ml-1 Hoechst 33342.  
 
 
At the time of conducting this experiment the cytotoxicity analyses of all the compounds on the 
MCF12A cell line had not been completed. The compounds chosen for this study, listed below, 
were selected as preliminary priority compounds based on their cytotoxic effect in MCF7 cells 
alone and therefore, this analysis was not conducted for all the priority compounds. MCF7 cells 
were treated with DMSO, paclitaxel, RUMB-007, RUMB-008, RUMB-010 and RUMB-015 for 
96 hours before being incubated with 5 µg.ml-1 Hoechst 33342 for 2 hours at 37°C. The cells 
were harvested by trypsinisation, washed with ice-cold PBS buffer (137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4.2H2O, 1.47 mM KH2PO4, pH 7.4) and analysed by flow cytometry using a 
FACSVantage SE flow cytometer. The Hoechst 33342 was excited at 350 nm and its 
fluorescence measured at 450 nm (Hoechst Blue) and 675 nm (Hoechst Red) and the same gate 
used to define the SP in the untreated MCF7 cells (Figure 17) was used to calculate the 
proportion of the SP in the MCF7 cells treated with DMSO, paclitaxel and selected algal 
compounds. The results are shown in Figure 18. 
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Figure 18: Comparison of the average percentage of the Hoechst 33342-excluding cells in 
MCF7 cells treated with selected marine algal compounds. 
The average percentage of the Hoechst 33342-excluding cells present in the rectangular gate in MCF7 cells treated 
with 0.25% DMSO, 100 nM paclitaxel, 33 µM RUMB-007, 29 µM RUMB-008, 68 µM RUMB-010 and 3 µM 
RUMB-015 for 96 hours and stained with 5 µg.ml-1Hoechst 33342 and analysed by flow cytometry. The data 
presented here are representative of replicate samples.  
 
The percentage of SP cells in the MCF7 cells treated with DMSO was 4.12%, higher than the 
0.1% to 2% that is generally accepted as being the proportion of cancer comprised of SP cells 
(Chuthapisith et al., 2009) but in the expected range for SP cells present in MCF7 cells which has 
been reported to be between 0.2% and 7.5% (Cariati et al., 2008; Engelmann et al., 2008; 
Patrawala et al., 2005). It was expected that treatment of MCF7 cells with paclitaxel would result 
in an apparent enrichment in the SP cells due to the inherent drug resistant nature of this 
population. However, there was a decrease in the percentage of these cells (0.47%) when 
compared with the DMSO sample. After treatment with 33 µM RUMB-007, 29 µM RUMB-008, 
68 µM RUMB-010 and 3 µM RUMB-015 for 96 hours, the percentages of Hoechst 33342-
excluding cells were 2.13%, 2.15%, 2.34% and 1.71% respectively. These values are lower than 
that of the DMSO-treated cells suggesting that these compounds may have had some cytotoxic 
effect on the SP; however this experiment would have to be repeated in order to verify that these 
compounds do, in fact, have a cytotoxic effect on the SP. It must be kept in mind that the media 
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used was not changed during the 96-hour treatment of the MCF7 cells with DMSO, paclitaxel 
and algal compounds. The media depletion that would have occurred during this time may have 
resulted in more stress upon the cells and therefore increased cell death. The observed cytotoxic 
effects, or lack thereof, of the compounds may be an overestimation as some of the cell death in 
both the SP and NSP may be a result of nutrient deficiencies. 
 
Due to its reliance on a biological process and its nature as a biological assay, the Hoechst 33342 
assay to investigate side populations is a very sensitive assay and may be affected by any changes 
in assay conditions and is especially sensitive to temperature (Goodell et al., 1996). Because 
Hoechst 33342 exclusion is an active and sensitive process falsely positive and negative results 
may occur. In addition, different numbers of cells were counted for each sample, making 
comparisons between the samples difficult. The validity of any conclusions drawn from these 
data is questionable because different cell numbers were counted for each sample, including the 
duplicate samples of cells treated with the same compound. The results for the different 
compounds cannot therefore be compared accurately and with confidence. Due to time 
constraints and equipment limitations this experiment was performed only once and therefore the 
reproducibility and robustness of this assay when used to determine the effect of the algal 
compounds on the SP is unknown. Validation of the results from this experiment would require 
repetition of the assay. The decrease in SP cells after treatment with paclitaxel to 0.47% when 
compared with the 4.12% in the DMSO-treated cells instead of the expected increase or 
enrichment for these cells (Li et al., 2008; Marotta and Polyak, 2009; Wicha et al., 2006) brings 
the accuracy, or the extent to which the results agree with known values, of this assay into 
question. As a result of the shortcomings encountered in the Hoechst 33342 assay for the side 
population in MCF7 cells, namely the highly sensitive nature of the assay, the difference in the 
numbers of cells counted and the fact that the priority compounds had not been selected at the 
time of doing this experiment, another assay in which the number of cells expressing the ABCG2 
transporter was investigated directly using an antibody against ABCG2. This assay was 
developed by our group and to our knowledge this is the first time this type of assay has been 
used to investigate the effect of novel compounds on CSC. Using an antibody against ABCG2, 
the transporter responsible for the efflux of the Hoechst 33342 dye, is specific for SP cells but 
unlike Hoechst 33342 this assay is not based on a biological procedure and so is less sensitive 
than the Hoechst 33342-exclusion assay.  
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4.2.2  Analysis of the percentage of ABCG2+ cells present in MCF7 cells 
after treatment with the priority compounds using flow cytometry 
MCF7 cells (1 x 106) cells were treated with DMSO, paclitaxel and RUMB-001, RUMB-002, 
RUMB-007, RUMB-010, RUMB-015 and RUMB-017/018 for 96 hours at 37°C at the 
concentrations indicated in the figure legend (Figure 19). The cells were harvested and incubated 
with 1 µg biotinylated anti-human CD338 (ABCG2) (BioLegend), following which they were 
stained with 2 µg streptavidin-FITC (Sigma) and analysed by flow cytometry using the Beckman 
Coulter FC 500 flow cytometer. The FITC was excited at a wavelength of 488 nm and its 
fluorescence emission measured at 530 nm. Single-colour histograms (Figure 19) were generated 
from the flow cytometry data and the gates used to define the ABCG2+ and ABCG2- populations 
in the DMSO sample were used to determine the percentage of the ABCG2- NSP and ABCG2+ 
SP populations in the samples treated with paclitaxel and selected indigenous compounds. The 
percentage of ABCG2+ cells present in each sample is shown in Figure 19. 
 
It has been reported that the SP of cancers make up between 0.1% and 2% of the total tumour 
mass (Chuthapisith et al., 2009; Fillmore and Kuperwasser, 2008) but other groups have found 
that the SP comprises between 0.2% and 7.5% of MCF7 cells (Engelmann et al., 2008; Patrawala 
et al., 2005). The DMSO treated sample showed an ABCG2+ population of 2.47% which is in the 
range reported for MCF7 cells (Engelmann et al., 2008; Patrawala et al., 2005) . Treatment of the 
MCF7 cells with paclitaxel was expected to result in an apparent enrichment for ABCG2+ cells, 
as these cells express the ABCG2 drug transporter and are reported to be resistant to 
chemotherapy drugs. The proportion of side population cells should increase relative to the rest of 
the tumour cells after treatment with a drug such as paclitaxel that has a high cytotoxicity in the 
bulk tumour cells but lower cytotoxicity to the CSC population (Dean et al., 2005; Hirschmann-
Jax et al., 2004; Zhou et al., 2001). 
 
The results of the cytotoxicity of the novel compounds against the SP are shown in Figure 19. 
The percentage of SP cells present in the MCF7 cells treated with paclitaxel was 4.8%, indicating 
an apparent enrichment in the SP cells as compared with the SP of 2.47% in the DMSO-treated 
cells. This is in accordance with reports in the literature (Li et al., 2008). The percentage of SP 
cells present in the MCF7 cells treated with RUMB-001, RUMB-002, RUMB-007 and RUMB-
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010 were 2.99%, 2.04%, 2.01% and 1.33% respectively. The percentage of SP cells in all of these 
samples were in the same range as the MCF7 cells treated with DMSO (2.47%), implying that 
these compounds have little effect on the cancer stem cell-containing side population in MCF7 
cells even though they showed cytotoxicity towards the bulk of the MCF7 cells (Chapter 3,Figure 
15). After treatment with RUMB-010 and RUMB-017/018, the ABCG2+ populations present in 
the MCF7 cell samples made up 0.67% and 0.9% of the total cell population respectively, 
indicating a drop in the percentage of SP cells relative to the untreated DMSO control (2.47%). 
This suggests that these compounds were able to preferentially target and reduce the SP. It would 
appear therefore, that RUMB-010 has a cytotoxic effect on both the bulk MCF7 cancer cells and 
the cancer stem cell-containing SP cells but not on the MCF12A normal breast epithelial cells. 
Interestingly, RUMB-017/018 had very little effect on both the MCF12A normal breast epithelial 
cells and the whole MCF7 breast cancer cells but did appear to have a cytotoxic effect on the SP. 
 
This assay was developed in our group during this project and therefore due to time constraints 
and equipment availability this experiment was performed only once. Therefore, it will be 
essential to repeat this experiment to validate the results. The results from the DMSO and 
paclitaxel samples do suggest this assay was successful, because they are in accordance with 
published values. The reproducibility of the assay, which is the degree to which the experiment 
gives the same results when repeated under the same conditions, however, is as yet untested. For 
a measurement to be valid it must be both accurate, meaning the measurement but be close to the 
actual value, and reproducible. The results obtained are accurate when compared with values 
reported in literature (Chuthapisith et al., 2009; Fillmore and Kuperwasser, 2008) but the results 
cannot be pronounced valid until the assay has been repeated. The design of the experiment may 
also be improved by changing the concentrations of priority compounds at which the MCF7 cells 
were tested. Analysis of the effect of the priority compounds on the SP at a range of different 
concentrations, from below the IC50 o above the IC50 value, may provide more conclusive 
information regarding the effect of the compounds on the SP and the minimum concentration 
required for cytotoxicity to the SP. Another assay that could be included is a kinetic analysis in 
which the effects of different concentrations of the compounds on the MCF7 SP cells are 
investigated over a pre-determined time course. 
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Figure 19: The effect of the priority compounds on the relative proportions of the ABCG2+ population in MCF7 cells 
Single-colour histograms generated from the flow cytometric analysis of the percentage of ABCG2+ cells in 20 000 MCF7 cells after treatment with selected algal 
compounds. The NSP is designated as „a‟ and the SP as „b‟. The numbers indicate the percentage of these cells within the total population. Cells were analysed after 
treatment with 0.25% DMSO (A), 10 nM paclitaxel (B), 80 µM RUMB-001 (C), 80 µM RUMB-002 (D), 40 µM RUMB-007 (E), 80 µM RUMB-010 (F), 10 µM 
RUMB-015 (G) and 300 µM RUMB-017/018 (H) for 96 hours. The DMSO sample (A) was used to define the gates for the ABCG2+ (2.47% in DMSO sample) and 
ABCG2- (97.53% in DMSO sample) populations and these gates were used for all subsequent samples. Flow cytometry was performed using the Beckman Coulter FC 
500 flow cytometer and data was collected in the FL1 channel. 
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4.3 Conclusion 
Two different techniques were used to investigate the effect of selected indigenous compounds 
on the SP of MCF7 breast cancer cells, namely the Hoechst 33342-exclusion assay (Goodell et 
al., 1996) and an assay developed during this project in which an antibody against ABCG2 was 
used to identify and analyse the SP in MCF7 cells by flow cytometry. While both of these assays 
make use of ABCG2 expression in the SP the antibody staining has some distinct advantages 
over the Hoechst 33342-exclusion assay. The efflux of Hoechst 33342 from cells is a biological 
process and as such is extremely sensitive to any changes in assay conditions, especially any 
fluctuations in temperature (Goodell et al., 1996). The staining of the MCF7 cells with an 
antibody against ABCG2 is not reliant on a biological process so the staining procedure is much 
less sensitive to environmental fluctuations and more reliable. This assay still retains the 
specificity for the SP but is more robust than the Hoechst 33342-exclusion assay making it a 
desirable alternative for use in the identification of the SP and the results obtained after treatment 
of the MCF7 cells with DMSO and paclitaxel justify the development of this assay for SP 
analysis. 
 
Not only is the antibody staining for ABCG2 to identify the SP a novel technique, but the 
indigenous algal compounds investigated for their cytotoxicity towards the SP are also novel 
compounds. Three of the priority compounds, namely RUMB-001, RUMB-002 and RUMB-007, 
had little apparent cytotoxicity towards the SP while RUMB-015 showed moderate cytotoxicity. 
RUMB-010 and RUMB-017/018 were the most effective at reducing the proportion of ABCG2+ 
MCF7 cells, with the percentage of these cells making up 0.67% and 0.9% respectively after 
treatment. This value is lower than that of the DMSO sample where the SP makes up 2.47% of 
the total cell population. It is important to note is that had RUMB-017/018 been excluded from 
this study based on its lack of cytotoxicity towards MCF7 breast cancer cells, its apparent 
cytotoxic effect on the cancer stem cell-containing ABCG2+ population would have been missed. 
It is possible; therefore, that other compounds that displayed little cytotoxicity in the bulk MCF7 
cell line, and in the MCF12A cell line, may have a cytotoxic effect on the SP in MCF7 cells and 
testing these compounds may provide further interesting results. These experiments however 
need to be repeated not only to confirm these results but also to test the reproducibility of the 
assay.  
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RUMB-010 and RUMB-017/018 are perhaps the most interesting of the priority compounds and 
may have the most potential as drug candidates should chemical modification be able to increase 
the cytotoxicity of these compounds in the NSP and/or SP in a cancer cell line. However further 
characterisation of the effects of these compounds on both the NSP and SP cells and the 
mechanisms by which they act would be required before a decision could be made regarding their 
potential as hit compounds.  
 
Work by other researchers has also indicated that it is possible to target the SP, for example three 
NF-κB pathway inhibitors that are capable of inhibiting the proliferation of CD44+CD24- MCF7 
cells (Zhou et al., 2008), which are thought to reside in the SP (Al-Hajj et al., 2003; Mylona et 
al., 2008). Interferon-alpha (IFN-α) has also been shown to reduce the percentage of SP cells 
relative to NSP cells in both ovarian cancer (Moserle et al., 2008) and adult T-cell leukaemia/ 
lymphoma (Kayo et al., 2007). Preliminary studies into the mechanism of toxicity of the priority 
compounds were then investigated using Western blot analyses for PARP cleavage and Hoechst 
33342 immunostaining for apoptotic nuclei. 
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5 DETERMINATION OF THE APOPTOTIC-INDUCING 
ABILITY OF THE PRIORITY COMPOUNDS 
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5.1 Introduction  
Apoptosis is a Greek word used to describe the falling or dropping off of a petal or leaf from a 
flower or tree. It is often mispronounced as the second „p‟ is silent. The second part of the word is 
a direct derivation of „ptosis‟, the Greek word for „falling‟. Originally called „shrinkage necrosis‟, 
apoptosis is defined as programmed cell death, a controlled process by which cells are lost from 
tissues in an effort to maintain tissue homeostasis which would otherwise be disrupted as a result 
of cell proliferation or damage from harmful cells. Apoptosis involves two distinct stages; first 
the formation of apoptotic bodies, during which nuclear and cytoplasmic condensation occurs, 
followed by the phagocytosis and degradation of the apoptotic bodies by the surrounding cells. 
Apoptosis causes no inflammation as is seen with necrosis and also allows for the recycling of 
cellular constituents (Kerr et al., 1972; Nagata, 1997).  
 
Apoptosis can occur either extrinsically, whereby cell death is induced by the presence of 
external signals or intrinsically, when cell death occurs as a result of the absence of external 
factors that inhibit apoptosis and  involves the release of cytochrome c from the mitochondrion 
and can occur through a number of different pathways (Figure 20) (Green and Reed, 1998; Kerr 
et al., 1972; Kroemer et al., 1995). The extrinsic and intrinsic apoptotic pathways converge in the 
final stages of apoptosis, the execution phase, during which caspases exert their function, 
cleaving numerous substrates (Elmore, 2007; Slee et al., 2001). A group of proteases known as 
the caspases are cysteine proteases responsible for apoptosis and once activated, caspases in turn 
activate an irreversible proteolytic signaling cascade that ultimately results in cell death  and over 
60 cellular proteins have been identified as caspase substrates (Morgan et al., 2002). It is during 
these final stages of apoptosis that caspase-3 cleaves poly(ADP-ribose) polymerase (PARP) 
(Elmore, 2007; Levrand et al., 2006; Regula and Kirshenbaum, 2005; Slee et al., 2001). (PARP), 
a 113 kDa nuclear zinc-finger DNA binding protein detects DNA strand breaks in cells and is 
involved in the poly(ADP-ribosyl)ation of nuclear proteins using NAD+ as a co-enzyme and is 
activated by binding to DNA ends or strand breaks (Boulares et al., 1999; Oliver et al., 1999). 
The cleavage of PARP produces two fragments; an 89 kDa fragment containing the active site of 
the enzyme and a 24 kDa fragment containing the DNA-binding domain of the enzyme 
(Kaufmann et al., 1993). This cleavage therefore abrogates the ability of PARP to respond to 
DNA strand breaks and as such is thought to contribute to the depletion of NAD and ATP in the 
cell, ultimately resulting in cell death (Boulares et al., 1999; Kaufmann et al., 1993; Oliver et al., 
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1999). PARP cleavage is therefore used as a marker of the late stages of apoptosis in cells 
(Kaufmann et al., 1993). The enzyme primarily responsible for the cleavage of PARP during 
apoptosis is caspase-3, one of the aforementioned proteins involved in the proteolytic cascade 
(Boulares et al., 1999). The cleavage site in PARP recognised by caspase-3 (DEVD) is highly 
conserved amongst different species, alluding to the importance of PARP cleavage during 
apoptosis (Boulares et al., 1999; Lazebnik et al., 1994; Le Rhun et al., 1998). 
 
 
Figure 20: Simplified schematic diagram showing the convergence of extrinsic and intrinsic 
apoptotic pathways. 
This schematic representation shows the convergence of the extrinsic and intrinsic apoptotic pathways on caspase-3 
during the final stages of apoptosis and the resultant cleavage action of caspase-3 on PARP [poly(ADP-ribose) 
polymerase]. In cases where caspase-3 is absent caspase-7 is sometimes capable of compensating for the lack of 
caspase-3 and of cleaving PARP (Elmore, 2007; Janicke et al., 1998; Slee et al., 2001). 
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One of the defining characteristics of malignant cells is their ability to evade apoptosis (Bertram, 
2000; Johnstone et al., 2002; Shao et al., 2004) and many chemotherapy drugs exert their effect 
on cancer cells by inducing apoptosis (Saunders et al., 1997). Originally the activation of 
apoptosis in breast cancer cells proved to be difficult, even when treated with these otherwise 
cytotoxic chemotherapeutic agents, but paclitaxel was one of few compounds able to successfully 
induce an apoptotic response in breast cancer cells (Saunders et al., 1997). The principal target of 
taxanes is thought to be the microtubule system and paclitaxel acts by binding to β-tubulin, 
thereby stabilizing microtubules and causing the cell cycle to arrest in the G2/M phase of the cell 
cycle, eventually resulting in apoptosis (Manfredi and Horwitz, 1984; Marone et al., 2001; 
Reshkin et al., 2003; Wang et al., 2000). It would make sense, therefore, that the ability of a 
compound to induce apoptosis in cancer cells would be one of the properties looked for when 
investigating the potential anti-cancer activity of novel compounds. 
 
The aim of the apoptosis assays was to identify which of the priority compounds, five of which 
were determined to be cytotoxic in the MCF7 breast cancer cell line (RUMB-001, RUMB-002, 
RUMB-007, RUMB-010 and RUMB-015), were able to elicit an apoptotic response (as indicated 
by PARP cleavage and Hoechst analysis) in these cells. 
 
5.2 Results and Discussion 
5.2.1 Detection of PARP in MCF7 cells after treatment with the priority 
compounds 
The ability of each of the selected priority compounds to induce apoptosis was investigated by 
Western blot analysis. MCF7 cells (1 × 105) were treated with serum starvation, 100 nM 
hydrogen peroxide (H2O2), 0.25% DMSO, 100 nM paclitaxel and the priority compounds at their 
IC50 values as determined by the cytotoxicity assays for 24 hours at 37°C, after which the 
cleavage of PARP was analysed by Western analysis (Figure 21). Serum starvation, H2O2 and 
paclitaxel were used as positive controls for the cleavage of PARP and DMSO was used as a 
negative control for PARP cleavage. 
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Figure 21: Detection of PARP cleavage in MCF7 cells after treatment with the priority 
compounds using SDS-PAGE and Western blot analysis. 
SDS-PAGE and Western blot analysis of full-length and cleaved PARP in MCF7 cells (1x105/lane) treated with 
serum starvation (SS), 100 nM H2O2 (H2O2), 0.25% DMSO (Lane 1), 100 nM paclitaxel (Lane 2), 58 µM RUMB-
001 (Lane 3), 65 µM RUMB-002 (Lane 4), 33 µM RUMB-007 (Lane 5), 68 µM RUMB-010 (Lane 6), 3 µM 
RUMB-015 (Lane 7) and 300 µM RUMB-017/018 (Lane 8) for 24 hours. Lane M shows a molecular weight marker. 
Full-length PARP (~130kDa) was detected in all samples but no cleaved PARP (~85kDa) was detected. 
 
 
Full-length PARP was detected but PARP cleavage was not detected in any of the MCF7 samples 
analysed by Western blot, including in the positive controls of serum starvation, H2O2 and 
paclitaxel, which are known to induce apoptosis in MCF7 cells (Egeblad and Jaattela, 2000; 
Perillo et al., 2000; Saunders et al., 1997). This result was consistently observed for repeated 
experiments, despite the reports in literature of apoptosis induction be serum starvation, 
paclitaxel and H2O2 (Egeblad and Jaattela, 2000; Perillo et al., 2000; Saunders et al., 1997)  After 
further investigation into these conflicting results it was found that MCF7 cells are caspase-3 
deficient as a result of a 47-bp deletion in the CASP-3 gene that abolishes the expression of 
caspase-3 (Jänicke, 2009; Janicke et al., 1998). Caspase-3 is required for PARP cleavage during 
apoptosis (Slee et al., 2001). Caspases-3, -6 and -7 are known as the executioner caspases and are 
thought to be responsible for the actual cell damage during apoptosis (Slee et al., 2001). It has 
been shown that caspase-6 and caspase-7 perform minor roles while caspase-3, the primary 
executioner caspase, is required for many of the proteolytic events that occur in the final stages of 
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apoptosis (Slee et al., 2001). In the absence of caspase-3 apoptosis in MCF7 cells occurs through 
a caspase-7-activated pathway and caspase-7 takes the place of caspase-3 as the primary 
executioner caspase in MCF7 cells (Twiddy et al., 2006) although it has been established that 
caspase-3 and caspase-7 perform distinct and different roles during apoptosis (Slee et al., 2001). 
It appears that in the above samples (Figure 21) caspase-7 was not able to compensate for the loss 
of PARP cleavage during apoptosis that would otherwise have occurred in the presence of 
caspase-3, although caspase-7-dependent PARP cleavage has been shown in MCF7 cells treated 
with staurosporine (Twiddy et al., 2006).  
 
The assays for PARP cleavage in MCF7 cells treated with the priority compounds were 
unsuccessful in determining the ability of these compounds to induce apoptosis. However, the 
data are consistent with the major role of caspase-3 in the proteolytic processing of PARP during 
apoptosis found by others (Jänicke, 2009; Slee et al., 2001). There were two possible alternative 
options available for determining whether the priority compounds induce apoptosis. These were 
to change the cell line and use one which does express caspase-3 and in which PARP cleavage is 
known to occur; or change the assay and use a technique that is independent of caspase-3. It was 
decided that the assay used would be changed as all the other experiments in this study were 
carried out using MCF7 cells and the data obtained for the cytotoxicity of the algal compounds in 
both the MCF7 cells and the MCF7 SP would thus be more comparable. A kinetic analysis 
incorporating a full range of dose concentrations assayed at different time points may allow for 
the eventual identification of PARP cleavage, especially if caspase-7 is only able to compensate 
for caspase-3 activity after a certain amount of time. 
 
5.2.2 Detection of apoptosis in MCF7 cells after treatment with the 
priority compounds using Hoechst 33342 immunostaining 
The morphological changes that allow the identification of a cell undergoing apoptosis include 
cell shrinkage which results in smaller cells with denser cytoplasm and more tightly packed 
organelles; chromatin condensation, the phase during which the nuclear material in the cell 
aggregates and the most characteristic feature of apoptosis; and membrane blebbing, a process in 
which membrane-bound cell fragments bud off from the cell as apoptotic bodies carrying some 
organelles and sometimes nuclear material (Elmore, 2007; Kerr, 1971; Kerr et al., 1972). The 
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ability of the priority compounds to induce apoptosis was determined by investigating whether 
treatment with the compounds induced chromatin condensation using staining with Hoechst 
33342, a nucleic acid stain, and immunofluorescence analysis. For the purposes of this study non-
apoptotic cells were defined as those showing intact nuclei and less intense staining. Apoptotic 
nuclei were defined as those nuclei showing chromatin condensation and therefore more intense 
staining, disintegration and the formation of potential apoptotic bodies containing nuclear 
material close to the cell (Figure 22). The difference between a non-apoptotic and an apoptotic 
nucleus is shown in Figure 22 where cells from the MCF7 cell line are treated with 100 nM 
paclitaxel for 48 hours. The cell representative of a non-apoptotic nucleus in Figure 22 was intact 
whereas the cell representative of an apoptotic nucleus shows chromatin condensation and 
nuclear disintegration and more intense staining. 
 
MCF7 cells (1 x105) were treated with 0.25% DMSO, 100 nM paclitaxel and the priority 
compounds at their IC50 values for 48 hours at 37°C following which they were stained with 
using 10 µg.ml-1 Hoechst 33342 and visualized using a Zeiss LSM META 510 laser scanning 
microscope at 405 nm (Figure 23). A total of 150 MCF7 cells from 3 randomly chosen fields 
were counted for each of the sample treatments, except in the case of RUMB-002 where only 69 
cells were counted because only 69 cells were present on the microscope slide. The number of 
apoptotic cells in each representative sample of 150 cells was counted, from which the percentage 
of apoptotic cells in each sample after treatment for 48 hours could be calculated (Figure 23).  
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Figure 22: Representative of (normal) non-apoptotic (A) and apoptotic (B) nuclei in MCF7 
cells using Hoechst-33342 staining. 
(A) Normal (non-apoptotic) and (B) apoptotic nucleus in MCF7 cells after treatment with 100 nM paclitaxel for 48 
hours and stained with 10 µg.ml-1 Hoechst 33342 and visualized at 60× magnification on a Zeiss LSM META 510 
laser scanning microscope at 405 nm. A: The non-apoptotic nucleus is intact and shows no obvious sign of nuclear 
condensation. B: An apoptotic nucleus showing both nuclear condensation, and therefore more intense nuclear 
staining, and nuclear disintegration, both characteristics of apoptosis.  
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Figure 23: Identification of Apoptotic Nuclei by Hoechst 33342 staining in MCF7 cells treated with novel indigenous compounds 
Representative images of apoptotic nuclear staining in MCF7 cells treated with 0.25% DMSO, 100 nM paclitaxel, 58 µM RUMB-001, 65 µM RUMB-002, 33 µM 
RUMB-007, 68 µM RUMB-010, 3 µM RUMB-015 and 300 µM RUMB-017/018 for 48 hours at 37°C and stained with 10 µg.ml-1 Hoechst 33342. The cells were 
visualized at 40× magnification using a Zeiss LSM META 510 laser scanning microscope. A total of 150 cells from three different fields of view were counted for each 
sample and the average percentage of apoptotic nuclei for each treatment in triplicate, shown in the bottom right of each image, was calculated. One field of view for 
each sample is shown here.  
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A total of 3.3% of the cells present in the DMSO negative control were judged as apoptotic while 
38.0% of the cells present in the positive control treated with 100 nM paclitaxel showed signs of 
apoptosis, namely chromatin condensation (and therefore brighter staining) and disintegration of 
the cell into apoptotic bodies. All the priority compounds tested appeared able to induce 
apoptosis in MCF7 cells, albeit at different levels. In the cells treated with the priority 
compounds, 38.7% and 26.7% of the cells in the RUMB-010 and RUMB-015 treated samples 
respectively appeared to be apoptotic according to the Hoechst staining pattern. These results 
imply that these compounds are able to induce apoptosis in MCF7 cells to approximately the 
same extent as paclitaxel. The percentage of apoptotic cells present in MCF7 cells treated with 
RUMB-001, RUMB-007 and RUMB-017/018 were calculated to be 14.0%, 16.0% and 12.7% 
respectively. While these compounds do not appear capable of inducing apoptosis to the same 
degree as paclitaxel, RUMB-010 and RUMB-015, they do activate apoptosis to a greater extent 
than seen in the DMSO negative control, which showed 3.3% apoptotic cells. Further 
experiments and statistical analysis would be required to determine whether these differences are 
significant. RUMB-002 appeared to be successful in inducing apoptosis with 37.7% of the cell 
present undergoing apoptosis, however only 69 cells were present in this sample and these few 
cells may not be representative of the effect of RUMB-002 on a larger population of cells.  
 
The MCF7 cells were treated with the priority compounds at their IC50 values. As such, it was 
expected that, if these compounds induce death solely through apoptosis, 50% of the cells in each 
sample would be show signs of apoptosis. Cells treated with RUMB-010 and RUMB-015 showed 
the highest incidences of apoptosis (38.7% and 26.7% respectively), however none of the priority 
compounds induced apoptosis in as many as 50% of the MCF7 cells as measured by this assay. 
Therefore, the mechanism by which these compounds bring about cell death may not be solely by 
apoptosis. It is possible that they induce cell death via other pathways rather that purely apoptotic 
pathways. In addition, the Hoechst 33342 assay used to identify apoptotic nuclei by 
immunostaining is a subjective assay and the difference between apoptotic and non-apoptotic 
cells is determined qualitatively. The Hoechst 33342 stain is non-specific and stains all nuclear 
material, not only that of cells undergoing apoptosis. In many cases it was difficult to determine 
whether a cell was undergoing apoptosis based on the features defined for apoptotic and non-
apoptotic cells for this assay, highlighting the bias of this assay. The Hoechst 33342 
immunostaining for apoptotic nuclei was used for this study as the Hoechst 33342 stain and other 
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reagents and equipment required were readily available whereas reagents required for more 
specific analyses were not. Data about the ability of the priority compounds to induce apoptosis 
in MCF7 cells was obtained and in some cases implied that certain compounds were able to 
induce apoptosis to a similar degree as paclitaxel, however we now appreciate the challenges 
presented by this assay as a result of the subjective nature of the interpretation of data. As such, 
no conclusive statements about the ability of these compounds to induce apoptosis can be made 
based on the data obtained from the Hoechst staining.  Further studies should allow better 
analysis of the ability of the priority compounds to induce apoptosis. 
 
There are many other assays that are specific for apoptosis that would have yielded less biased 
and more reliable results. The combination of Hoechst 33342 and propidium iodide, which also 
stains DNA, are often used for the detection of apoptotic cells versus necrotic cells by 
fluorescence microscopy. Theoretically, the Hoechst 33342 should allow a distinction to be made 
between apoptotic and non-apoptotic cells and the propidium iodide, as a result of being 
membrane impermeable, only stains the DNA of dead cells. This should allow the identification 
of live cells, cells undergoing apoptosis and dead cells although some of the difficulties 
encountered when using Hoechst 33342 only will most likely be present when using Hoechst 
33342 in conjunction with propidium iodide. There are other techniques more specific for 
apoptosis. One such technique exploits the translocation of phosphatidylserine from the inner 
leaflet of the plasma membrane to the cell surface, a universal and early event in apoptosis.  
Annexin V, for example, binds to phosphatidylserine and if conjugated to a fluorescent label 
would allow the accurate identification of cells undergoing apoptosis by both fluorescence 
microscopy and flow cytometry (van Engeland et al., 1998; Zhang et al., 1997). Another 
technique commonly used to identify apoptosis is the TUNEL assay. The execution phase of 
apoptosis results in DNA fragmentation and the TUNEL assay is based on the detection of DNA 
fragmentation by terminal deoxynucleotidyl transferase, which catalyses the addition of dUTPs to 
any nicks present in DNA (Elmore, 2007; Gavrieli et al., 1992). Apoptotic cells can thus be 
identified by using fluorescently labeled dUTPs and immunostaining for fluorescence 
microscopy (Gavrieli et al., 1992). This technique has two main drawbacks. Firstly, it is based on 
an event that happens late in apoptosis and so cells undergoing early apoptosis may be missed. 
Also, cells that have been subjected to severe DNA damage will also be labeled with the 
fluorescent dUTPs, giving false positives.  
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The Annexin V assay would be preferred should this experiment be repeated as it is specific for 
apoptosis and is based on an early event during the apoptotic pathway and so cells in the early 
stages of apoptosis would not be missed. In addition to using a technique specific for apoptosis, 
the design of the experiment may also be improved upon. The MCF7 cells were treated with the 
priority compounds at only their IC50 value and only after 48 hours. Increasing the range of 
concentration of treatment may provide more useful information regarding the minimum 
concentration required to induce apoptosis. A further change that may improve the quality and 
validity of this assay may come from testing different concentrations of the priority compounds 
over different time periods for the induction of apoptosis.   
 
5.3 Conclusion 
Induction of apoptosis is a way of targeting death in a particular cell without inducing an immune 
response that will lead to the death of nearby cells. All the priority compounds tested were 
predicted as capable of inducing apoptosis to some extent in the MCF7 cells, as determined by 
the immunofluorescent identification of nuclear condensation using Hoechst 33342. RUMB-010 
and RUMB-015 appeared to be the most successful at inducing apoptosis when treating MCF7 
cells with these compounds at their IC50 values with the percentage of apoptotic cells present in 
cells treated with these compounds being in the same range as the percentage apoptotic cells in 
the sample treated with 100 nM paclitaxel. RUMB-002 also appeared successful at inducing 
apoptosis but as a result of the small cell numbers counted for this sample it is not comparable 
with the other samples and in order to determine the ability of RUMB-002 to induce apoptosis 
this experiment would need to be repeated. The remaining three priority compounds, RUMB-001, 
RUMB-007 and RUMB-017/018 were able to induce apoptosis, albeit not to the same extent as 
the aforementioned compounds however, this technique is limited and so further analysis would 
be required to determine this conclusively.  
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6.1 Results Summary  
The aim of this study was to screen a group of novel organic molecules isolated from algae off 
the East Coast of South Africa for their activity in cells representative of normal healthy cells and 
cancer cells using the MTT cell proliferation assay, as well as in the cancer stem cell containing-
SP using flow cytometry. A summary of the characteristics of the novel algal compounds and the 
cytotoxicity in MCF12A and MCF7 cells and the SP analyses discussed above is presented below 
in Table 3. Based on these data, we proposed to carry out preliminary investigations into the 
mechanism by which any cytotoxic compounds acted in the cancer cells. The approach that was 
developed in this study included the investigation of the effects of the compounds on the bulk 
tumour and the SP, which is believed to contain the cancer stem cell population responsible for 
the maintenance of the tumour.  
 
Compounds with differential cytotoxicities in the MCF12A breast epithelial (representing normal 
cells) and MCF7 breast cancer cell lines were identified using the MTT cell proliferation assay. 
Most of the novel marine organic molecules tested were more toxic towards MCF7 cells than not 
the MCF12A cells, although one compound was toxic to the MCF12A cells to a greater extent 
than to the MCF7 cells (RUMB-005), one compound was highly cytotoxic to both cell lines 
(RUMB-015) and one compound was apparently non-toxic to either cell line (RUMB-017/018). 
Six compounds (termed priority compounds) were selected for further analysis (Table 3). Four of 
these compounds, namely RUMB-001, RUMB-002, RUMB-007 and RUMB-010, exhibited 
differential toxicity in MCF7 and MCF12A cells with at least three-fold higher cytotoxicity in the 
MCF7 breast cancer cells than in the MCF12A breast epithelial cells. RUMB-015, which had the 
lowest IC50 value in both cell lines, and RUMB-017/018, which exhibited no apparent 
cytotoxicity to either cell line, were also selected as priority compounds. It was anticipated that 
these compounds would be used to validate future assays, as they were from the same class of 
molecules as the other priority compounds and could therefore represent positive or negative 
controls for cytotoxicity 
 
 
 
 
Jessica C Lawson 2010 
98 
 
Table 3: A summary of the cytotoxicity of the algal compounds in MCF12A and MCF7 cells 
and the effect of the priority compounds on MCF7 SP cells 
Compound Toxicity in 
MCF12A cells 
(MTT assay) 
Toxicity in 
MCF7 cells 
(MTT assay) 
Toxicity to SP 
cells (Hoechst 
33342-
exclusion assay) 
Toxicity to SP 
cells (ABCG2 
antibody 
assay) 
RUMB-001 Low High Not tested Low 
RUMB-002 Low High Not tested Low 
RUMB-003 Low Moderate Not tested Not tested 
RUMB-004 Low Moderate Not tested Not tested 
RUMB-005 High High Not tested Not tested 
RUMB-007 Low High Low Low 
RUMB-008 Moderate High Low Not tested 
RUMB-010 Low High Low High 
RUMB-015 High High Low High 
RUMB-
017/018 
Low Low Not tested High 
 
RUMB-005 was more toxic to the normal MCF12A cells than to the MCF7 breast cancer cells. 
This was considered to be an undesirable property for a potential novel hit compounds and so 
RUMB-005 was not selected as a priority compound. Interestingly, the data for paclitaxel-treated 
MCF12A and MCF7 cells, however, indicated that paclitaxel, which has an IC50 of approximately 
100 nM in MCF7 cells, was more toxic to the MCF12A cell line, in which it was calculated to 
have an IC50 of 5.36 nM, than to the cancer cells. This once again highlights the potential 
unsuitability of MCF12A cells as a „normal‟ control because of the growth stimulants these cells 
required for proliferation. Paclitaxel is currently used as a chemotherapy drug. One of the 
features of cancer cells is their ability to evade apoptosis, and so perhaps the anti-apoptotic 
mechanism in MCF7 cells enables them to tolerate more of a toxic compound than normal cells 
that lack such mechanisms. There are no reports of the IC50 value for paclitaxel in MCF12A cells, 
despite the fact that MCF12A cells are often used as a „normal‟ cell control in cytotoxicity 
analyses (Lin et al., 2004; Van Zijl et al., 2008).  
 
Determination of the effect of the selected priority compounds against the SP was achieved using 
an antibody against the SP-specific ABCG2 and flow cytometry. Three of the priority 
compounds, RUMB-001, RUMB-002 and RUMB-007 had no apparent effect on the SP, as 
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indicated by the fact that the size of the ABCG2+ population in these treated cells was similar to 
that observed in the untreated cells. Three compounds, namely RUMB-010, RUMB-015 and 
RUMB-017/018, appeared to potentially target the SP in MCF7 cells, as indicated by a decrease 
in the percentage of ABCG2+ cells in the treated cells (0.67%, 0.86% and 0.9%, respectively) 
compared with the untreated cells (2.47%). However, the assay in which the effect of the priority 
compounds on the ABCG2+ SP of MCF7 cells was determined was developed during this project 
and due to time and equipment constraints this study was completed only once. Further analyses 
would be required to confirm and validate the data obtained as well as to ensure the 
reproducibility and robustness of the assay. 
 
The summary shown in Table 3 allows for the identification of any compounds that appear to 
have the most potential as high priority hits for development into lead compounds. The results 
presented here suggest that RUMB-010 and RUMB-017/018 may be most promising as potential 
hit compounds; RUMB-010 because it is non-toxic to the MCF12A „normal‟ cells but toxic to 
both the MCF7 cancer cells and the MCF7 SP and RUMB-017/018 because it seems to be 
capable of specifically targeting the SP. An analysis of the effect of the non-priority compounds 
on the SP of MCF7 cells using the assay developed during this study may result in the 
identification of further compounds able to specifically target the SP. Before these compounds 
can be considered hit compounds and move on to become potential lead compounds further 
analysis is required. It would also be essential that both RUMB-010 and RUMB-017/018 are 
tested for toxicity in both embryonic and adult stem cells. These compounds exhibited 
cytotoxicity towards the CSC-containing SP in MCF7 cells and may therefore have a toxic effect 
on either embryonic or adult stem cells or both. Since adult stem cells are the source of 
maintenance of most adult tissues  a drug that targets these cells would most likely have 
extensive and serious detrimental effects on normal tissues (Beltrami et al., 2009; Clarke and 
Frisén, 2001; Zhao et al., 2008). The mechanism of toxicity and the cellular target of the 
compound must be identified and chemical modification to enhance the cytotoxic effects on the 
target cells can be carried out. For example, the role of the halogen groups in the cytotoxicity of 
the compounds may be determined by successively substituting the bromine and chlorine groups 
with proton or methyl groups. Any change in the cytotoxicity of the derivative compounds could 
then be attributed to the substitution, shedding light on the role played by the electronegative 
halogen groups. The chemical integrity and stability of the compound must be analysed and 
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optimized and the structure-activity relationship of the compound must be assessed (Bleicher et 
al., 2003). The SAR of over 800 multidrug resistance reversal agents for the treatment of cancer 
were reviewed using in silico structure-activity analyses (Klopman et al., 1997). The information 
provided by SAR analyses can lead to the development of more effective drugs. For example 
after conducting SAR studies on glutamine analogues that were membrane impermeable, it was 
found that linking the analogues to a peptide rendered them membrane permeable, and thus able 
to enter the cell and act accordingly (Klopman et al., 1997; Marshall et al., 2003). Similar SAR 
studies could be conducted these algal compounds in silico using molecular modelling software 
or by the generation of successive derivatives of the test compounds (Bleicher et al., 2003; 
Klopman et al., 1997; Marshall et al., 2003).  
 
A preliminary investigation into the mechanism by which these priority compounds exert their 
cytotoxicity by immunostaining using Hoechst 33342 revealed that all the priority compounds 
seemed capable of inducing apoptosis, albeit to different extents. Two of the compounds, namely 
RUMB-010 and RUMB-015, appeared to be able to induce apoptosis in the MCF7 cells to the 
same extent as the chemotherapeutic drug paclitaxel. RUMB-001, RUMB-007 and RUMB-
017/018 were able to induce apoptosis to some extent but not to the same degree as paclitaxel or 
RUMB-010 and RUMB-015. The data obtained from the MCF7 cells treated with RUMB-002 in 
this study was inconclusive and in order to determine whether RUMB-002 is capable of inducing 
apoptosis and if so to what extent repetition of the study and further analysis would be required. 
The Hoechst 33342 immunostaining used for the detection of apoptotic nuclei is a non-specific 
and biased assay and for the results to be confirmed and validated another more specific assay 
and repeated experiments would be required. The results from this study were not included in 
Table 3 as the technique attempted here was flawed and the data obtained was inconclusive. 
Work into the ability of these compounds to induce apoptosis is ongoing and is currently being 
investigated in MDA-MB-231 cells, a breast cancer cell line in which the IC50 values of these 
compounds have also been determined.  
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6.2 Novel algal compounds as potential anti-cancer and anti-CSC 
agents and identification of potential hit compounds 
Halogenated monoterpenes are a class of naturally occurring acyclic organohalogens found only 
in 3 genera of red algae; Plocamium, Ochtodes and Portieria. Over one hundred halogenated 
monoterpenes have been isolated and characterised, some of which have been demonstrated to 
have anti-cancer properties (de Ines et al., 2004; Fuller et al., 1992; Polzin et al., 2003; Wise and 
Croteau, 1999), making them potential scaffolds for future drug design.  
The only compound tested here that was not a halogenated monoterpene was RUMB-010, or 
sargaquinoic acid, a tetraprenylquinone isolated from the brown alga Sargassum heterophyllum.  
The components of the cell that these algal compounds target and the mechanism by which they 
act are largely unknown, but are very important in the identification of potential novel drugs 
(Naylor et al., 1983; Wise and Croteau, 1999). There is some evidence in literature that 
sargaquinoic acid (RUMB-010) induces apoptosis in certain cells and has been demonstrated to 
do so in human keratinocyte cell line HaCaT as well as in mice skin cells (Hur et al., 2008).  
Analysis of major signalling pathways or immunoprecipitation should enable the determination 
of the mechanism of cytotoxicity of these compounds and the cellular component targeted by the 
compounds. Three signalling pathways that could be investigated are the Hedgehog, Notch and 
Wnt signalling pathways, all of which have already been implicated in many cancers, including 
breast cancer (Evangelista et al., 2006; Kasper et al., 2009; Zardawi, 2009). These three pathways 
have also been proposed to play important roles in the self-renewal and survival of CSC (Howe 
and Brown, 2004; Kopper and Hajdu, 2004; Liu et al., 2005; Zardawi, 2009). A simple way of 
investigating the effect of the priority compounds on these pathways would be to select a protein 
essential to the pathway, for example β-catenin in the Wnt pathway, and determine whether the 
protein is affected (expression level or localisation) after treatment with the compounds using 
Western blot analyses (Prasad et al., 2007; Wang et al., 2009). This could be done for all the 
major proteins in the pathways. This technique has been used successfully to investigate the 
disruption of Hsp90 associations with its client proteins in various cancer cell lines by certain 
compounds (Li et al., 2006; Luo et al., 2007; Niikura et al., 2006; Zhang et al., 2008). 
Alternatively, the compounds could be conjugated to agarose and used as the bait in pull down 
assays to identify cellular components to which the compound binds (Golubovskaya et al., 2008; 
Wang et al., 2009).  
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The structures of the halogenated monoterpenes and sargaquinoic acid bear little chemical and 
structural resemblance to those drugs currently being used in chemotherapy, which often contain 
multiple rings and nitrogen groups and have IC50 values in the nanomolar range (Sigurdsson et 
al., 1986; Tian et al., 2004; Wang et al., 2006; Yayoi et al., 2009). The algal compounds tested in 
this body of work had IC50 values in the micromolar range, which would be considered too high 
for a potential hit compound. Elucidation of the mechanism of cytotoxicity and the specific 
targets of these compounds within the cell may be able to inform rational chemical modification 
to enhance the cytotoxicity of these compounds in the cancer cells and potentially even the CSC. 
Chemical modification has been widely used to alter the properties of certain compounds and to 
increase the toxic effects of anti-cancer drugs (Gomez-Orellana, 2005; Majumdar and Mitra, 
2006). Perhaps one of the most successful chemical modifications is that of 17-AAG, a derivative 
of geldanamycin and inhibitor of Hsp90, that has shown promise as a potential breast cancer 
treatment in clinical trials (Nimmanapalli et al., 2001; Schulte and Neckers, 1998; Yayoi et al., 
2009). Paclitaxel derivatives have also been investigated for water solubility and increased 
cytotoxicity and some derivatives have been shown to be successful in this regard (Rose et al., 
1997; Safavy et al., 1999). Other derivatives of chemotherapeutic drugs that have shown 
enhanced cytotoxicity include derivatives of gambogic acid and CPT-11, a derivative of 
camptothecin (Tsuruo et al., 1988; Wang et al., 2009; Zhang et al., 2004). It is not unreasonable, 
therefore, to consider the possibility that chemical modification of the novel marine organic 
compounds tested for cytotoxicity in MCF7 cells could improve the solubility of the compounds 
in water as well as enhance their anti-tumour activity. Structural comparison of the algal 
compounds with current chemotherapeutics may also provide a basis for rational chemical 
modification. The electronegativity of these compounds is one of the features on which 
chemotherapy relies (Holshouser et al., 2002; Maini et al., 1997; Wu et al., 2000) and so 
modification of the electronegativity of the algal compounds may enhance their cytotoxic 
activity. One potential modification is the substitution of one of the end groups on the algal 
compounds for a group which is highly electronegative and one which is not electronegative and 
investigating the change in cytotoxicity of these compounds in cancer cells seen as a result of 
higher or lower electron withdrawing capabilities, enlightening us as to whether electronegativity 
is the cytotoxic factor.  Modification of the algal compounds to include a nitrogen group may also 
have some effect on the cytotoxicity of the algal compounds in cancer cells.   
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Sargaquinoic acid (RUMB-010) has been shown to induce apoptosis in HaCaT and mice skin 
cells (Hur et al., 2008) but in other cell lines it appears to promote neurite outgrowth, especially 
in PC12D cells, a cell sub-line derived from the pheochromocytoma of rat adrenal medulla 
(Kamei and Tsang, 2003; Tsang et al., 2001). RUMB-010 appeared capable of specifically 
targeting and removing the SP in MCF7 cells but this was determined only by investigating the 
proportions of SP cells to NSP cells using flow cytometry. This technique is limited as it gives no 
indication as to whether RUMB-010 induced the cells to undergo apoptosis, removing them by 
killing them, or if it forced the undifferentiated cells in the SP to differentiate, lose their SP 
markers and appear in the NSP proportion. The isolated SP would have to be treated with 
RUMB-010 as a purified fraction in order to determine whether the compound induces cell death 
or forces the cells to differentiate. Unfortunately, SP cells are prone to asymmetric division 
because of the CSC population that resides within the SP. In order to determine the effect of a 
compound on the SP alone a culture method that prevents the asymmetric division of the cells 
would have to be developed. It would also be necessary to validate that the SP is in fact enriched 
for CSC. This could be achieved by isolating the SP cells using flow cytometry and then 
investigating the expression of proposed breast CSC surface phenotypes, for example 
CD44+CD24- and ALDH1 (Al-Hajj et al., 2003; Ginestier et al., 2007; Mylona et al., 2008). 
 
6.3 A hit-to-target approach for screening potential anti-cancer 
and anti-CSC agents 
Hit-to-target approaches are commonly used in drug development and are dependent on high-
throughput screening (Starkuviene and Pepperkok, 2007). The approach developed in this study 
is a novel hit-to-target approach that can be used for the screening of potential anti-cancer and 
anti-CSC compounds. This approach makes use of three distinct cell types for screening 
experiments – normal non-cancerous cells, cancer cells and the CSC-containing SP to screen 
novel compounds and has an advantage in that it incorporates components that may have been 
neglected in the past, in particular the effect of compounds on the SP that may reside within 
tumours. The results presented in this thesis show that the type of assay used to screen potential 
drugs may influence the data collected and so it is important when screening novel compounds 
for potential hit compounds that the most specific, reproducible and robust assays are used. The 
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shortcomings of certain assays are also highlighted in this body of work and relate to the types of 
assays and cell models used for the assessment of cytotoxicity.  
 
The results from the MTT cell proliferation assay were used to select priority compounds that 
were at least three fold more cytotoxic in the MCF7 cancer cells than in the normal MCF12A 
cells. RUMB-017/018 did not meet the criteria defined for priority compounds but was selected 
for further studies based on its lack of cytotoxicity in both the MCF12A and MCF7 cells. It was 
later found that this compound appeared able to specifically target the SP in MCF7 cells. Other 
compounds that were not selected as priority compounds due to their insufficient cytotoxicity 
towards the MCF7 cancer cells may also be able to specifically target the SP but based on the 
results of the MTT cell proliferation assay, were disregarded for further analysis during this 
study. This raises the question as to how many other compounds have been discarded in the past 
based on their lack of potent cytotoxic activity in cancer cells without having been tested on the 
SP or the CSC subpopulations.  
 
There are ways in which this approach can be improved; mostly by the use of different and more 
specific assays. An alternative to the MTT cell proliferation assay is an adaptation of the MTT 
assay. The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay results in the production of a water soluble product (Cory et al., 1991). The 
MTS assay has two distinct advantages over the MTT assay: MTS is more efficiently reduced 
than MTT and the water soluble product removes the possibility of any toxicity to the cells of the 
insoluble formazan produced in the MTT assay (Cory et al., 1991). The MTS assay also 
eliminates the need for the solubilisation step that is required in the MTT assay. Another 
technique that could be used is CASY cell counting technology, which is based on the integrity of 
the plasma membrane of the cell (Lindl et al., 2005). The plasma membrane of viable cells is 
intact while that of dead cells is broken and contains pores. Application of a low voltage electric 
field to a cell sample enables the distinction between viable and non-viable cells (Cory et al., 
1991; Lindl et al., 2005). An electric current cannot pass through the intact plasma of a viable cell 
but can pass through the pores present in the membrane of a dead cell (Cory et al., 1991; Lindl et 
al., 2005). One of the main advantages of the CASY cell counting technique is the speed at which 
data is obtained and it reproducibility (Cory et al., 1991; Lindl et al., 2005).  
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The analysis of the SP by flow cytometry and staining with an antibody against ABCG2+ is a 
newly developed assay that has not previously been used for the identification and analysis of the 
SP of cancer cell lines. It is also the first time that an assay of this nature has been used to 
investigate the effect of compounds, novel or otherwise, on the SP within a tumour. The main 
advantage of this antibody-based approach over the Hoechst 33342-exclusion assay is that it is 
not reliant on a biological process and so is much less sensitive to false negatives and therefore 
more reliable. Validation of both the development of the assay and the results presented here 
would require repetition of the assay. In addition to being repeated, the assay requires further 
validation regarding the non-specific binding of the ABCG2 antibody. Non-specific binding of 
this antibody would produce false positives, thus skewing the results. The determination of the 
extent to which this antibody is susceptible to non-specific binding could be achieved by using a 
SP-deficient cell line or by separating the SP and the NSP prior to incubation with the antibody 
against ABCG2. Isolation and culture of the CSC-enriched SP would allow further 
characterisation of the effects of compounds on the SP, as well as confirmation of the effects 
already seen in SP analyses conducted in situ, and calculation of IC50 values for the toxic 
compounds. This would also allow validation of the SP as being enriched for CSC using CSC-
specific markers (such as CD44) and functional assays (anchorage-independent growth) (Al-Hajj 
et al., 2003; Mylona et al., 2008).  
 
A better indication of the mechanism of action of the compounds could be obtained using a 
different and more reliable apoptosis detection technique. One such technique is the staining of 
the cells with Annexin V conjugated to a fluorescent molecule. Annexin V binds to 
phosphatidylserines which are translocated from the inner plasma membrane to the surface of the 
cell early in apoptosis and so staining with Annexin V conjugated to a fluorescent molecule 
allows for the identification of cell undergoing apoptosis (van Engeland et al., 1998; Zhang et al., 
1997). 
 
Another way in which this approach could be improved is by using paired cell lines as the model 
system, as opposed to the MCF12A and MCF7 cell lines. The disadvantages of using MCF12A 
cells, which need various stimulants in order to grow in culture, have already been discussed 
(Chapter 3). Using a cell line that is a true normal equivalent of the cancer cell line used is 
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important.  For instance, these normal equivalents should grow in culture and should ideally not 
require complex external stimulants to ensure that any effect on the cells observed was a result of 
the test compounds acting on the cells themselves and not a result of the compounds interfering 
with one of the stimulatory factors. The use of cancerous and non-cancerous paired cell lines will 
also account for any difference that arise due to a difference in the overall genetic background of 
the cell. For example, the paired cell lines, Hs578Bst and Hs578T, are a good example of normal 
and cancerous breast cell lines (respectively) and which have the same origin (Hackett et al., 
1977; Smith, 1979). 
 
6.4 Importance of identifying anti-CSC and anti-breast CSC 
agents  
Cancer is one of the leading causes of death worldwide and as the most commonly diagnosed 
malignancy in women, breast cancer is of global importance (Garcia et al., 2007). In southern 
Africa, breast cancer comprised 10.% of the 78 100 new cancer cases diagnosed in 2007and only 
32% of women diagnosed with advanced breast cancer in southern Africa survive more than five 
years (Garcia et al., 2007). The major cause of death in breast cancer patients in metastasis and 
there is no standardized treatment for metastatic breast cancer yet available, although 
trastuzumab, a monoclonal antibody directed against HER-2, has been recently used to 
successfully treat HER-2 positive early and metastatic breast cancer (Emens, 2005; Gralow, 
2005; Hall and Cameron, 2009; Neyt et al., 2008).  
 
Recently discovered evidence that supports the cancer stem cell theory of cancer development 
has implications for the treatment of cancer and rapid advancement in this field has provided 
hope for the development of an effective and reliable anti-cancer treatment as the only way to 
completely remove a tumour will be to remove the cell population sustaining that tumour (Al-
Hajj et al., 2004; Klonisch et al., 2008). The cancer stem cell theory of cancer proposes that CSC 
are self-renewing and resistant to chemotherapy and are believed to be responsible for tumour 
initiation and maintenance (Marotta and Polyak, 2009; Wicha et al., 2006). Because of their 
resistance to chemotherapy, after treatment of a tumour with conventional chemotherapy drugs 
the CSC remain behind and are able to repopulate the tumour, leading to relapse (Marotta and 
Polyak, 2009; Wicha et al., 2006) which has prompted exploration into new drugs that are able to 
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target and kill CSC (Chuthapisith et al., 2009; Li et al., 2008). Any treatment capable of targeting 
and killing CSC has the theoretical potential to effectively treat cancer, especially if such a 
treatment is used in conjunction with conventional chemotherapy. Unfortunately, no such 
treatments are yet available although research into compounds that are specifically able to target 
CSC is being undertaken. Two Hsp90 inhibitors, 17-AAG and 17-DMAG, have been 
demonstrated to be capable of inhibiting the growth of glioma stem cells and sensitising BRCA1 
breast cancers to conventional chemotherapeutics respectively (Sauvageot et al., 2009; Wright et 
al., 2008) and inhibitors of the NF-κB pathway have been shown to preferentially inhibit the 
proliferation and colony forming abilities of the putative CD44+CD24- CSC from the MCF7 cell 
line (Zhou et al., 2008). 
 
The search for effective new anti-cancer treatments is therefore ongoing and natural products 
have historically been a rich source of treatments for many human diseases (Newman et al., 
2003). While the idea of cancer stem cell specific anti-cancer treatments is promising, should 
compounds capable of effectively and specifically targeting and killing CSC be identified, a 
variety of other questions will need to be answered. The differences between normal adult stem 
cells and CSC and the properties thereof need to be defined in order to fully understand CSC, the 
mechanisms by which they operate and the most effective way in which they can be targeted for 
anti-cancer therapy (Trosko et al., 2005; Zhao et al., 2008). There is still much more work that 
needs to be done in order to not only understand CSC and their biology but also in the discovery 
and development of a specific and effective therapy aimed at removing the cancer stem cell 
population. This does not, however, exclude the ongoing work into novel therapies aimed at the 
bulk of the tumour cells. The search for new anti-cancer drugs is ongoing in an effort to find 
treatments that are more effective in killing the cancer cells but have fewer adverse side effects 
on healthy cells. The evidence supporting the existence of CSC provides an attractive target for 
drug development. 
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8.1 APPENDIX 1 
 
8.1.1 Reagents Used 
Table 4: Reagents Used 
  
Dulbecco’s Modified Eagle Medium (DMEM)  Gibco, USA 
Ham’s F10  Sigma Aldrich, USA 
Foetal calf serum (FCS)  PAA Laboratories, 
USA 
L-glutamine  Gibco, USA 
Penicillin-Streptomycin  BioWhittaker, USA 
Epidermal growth factor (EGF)  Sigma Aldrich, USA 
Cholera toxin  Sigma Aldrich, USA 
Hydrocortisone  Sigma Aldrich, USA 
Insulin  Sigma Aldrich, USA 
Trypsin/ethylenediaminetetraacetic acid (EDTA)  Sigma Aldrich, USA 
Phosphate buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 
4.3 mM Na2HPO4.2H2O, 1.47 mM KH2PO4, pH 7.4) 
Not applicable 
Tris-buffered saline-Tween (50 mM Tris, 150 mM NaCl, 0.1% 
Tween-20, pH 7.5) 
Not applicable 
Purified mouse anti-human PARP [poly (ADP-ribose) 
polymerase]  
BD Pharmingen, USA 
ECL Advance Western Blotting Kit  GE Healthcare, USA 
Hoechst 33342  Invitrogen, USA 
Biotin anti-human CD338 (ABCG2)  BioLegend, USA 
Streptavidin-FITC  SigmaAldrich, USA 
Propidium iodide  Fluka, USA 
Reserpine  Sigma Aldrich, USA 
MTT Cell Proliferation Kit I Roche, USA 
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8.1.2 Compound Dilution Calculations 
All compounds received were diluted in 50 µl DMSO to give stock concentrations shown in 
Table 5. A 1µl volume of each compound was mixed with different amounts of serum-containing 
DMEM (Table 6: Amount (µl) of DMEM added to 1 µl of stock compound to give a 1 mM) such 
that the concentration of the mixture was 1 mM. 
Table 5: Stock concentrations (mM) of novel marine compounds dissolved in DMSO 
RUMB Code Stock 
(mM) 
RUMB-001 87.688 
RUMB-002 125.194 
RUMB-003 40.353 
RUMB-004 253.571 
RUMB-005 193.77 
RUMB-007 625.75 
RUMB-008 119.99 
RUMB-010 18.84 
RUMB-015 79.1 
RUMB-017/018 507.01 
 
Table 6: Amount (µl) of DMEM added to 1 µl of stock compound to give a 1 mM  
RUMB Code DMEM  
(µl) 
Calculation 
RUMB-001 86.688 The amount of 1 mM solution required to make the 100 µM 
compound dilution required for the MTT assays was 
calculated using the equation  c1v1=c2v2  where c1 = 
initial concentration (1 mM), v1 = volume required, c2 = final 
concentration (0.1 mM) and v2 = final volume (1.5 ml) 
Therefore: c1v1=c2v2  1 mM × v1 = 0.1 mM × 1.5 ml 
v1 = 0.15 ml v1 = 150 µl of 1 mM solution + 1350 µl 
DMEM 
RUMB-002 124.194 
RUMB-003 39.353 
RUMB-004 252.571 
RUMB-005 192.77 
RUMB-007 624.75 
RUMB-008 118.99 
RUMB-010 17.84 
RUMB-015 78.1 
RUMB-017/018 506.01 
The same equation was used to calculate the amount of 1 mM solution required to make the 50 
µM compound dilutions, the amount of 50 µM solution required to make the 5 µM compound 
dilutions and the amount of 5 µM solution required to make the 0.5 µM compound dilutions 
required for the MTT assays.  
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8.2 SDS-PAGE Resolving and Stacking Gel Constituents 
8.2.1 12% Resolving Gel 
3.2 ml dH20 
2.6 ml 1.5 M Tris (pH 8.8)  
4 ml 30% acrylamide 
100 µl 10% SDS 
100 µl 10% ammonium persulphate (APS) 
20 µl TEMED 
Final volume = 10ml 
 
 
8.2.2 4% Stacking Gel 
 6.1 ml dH20 
2.5 ml 0.5 M Tris (pH 6.8)  
1.3 ml 30% acrylamide 
100 µl 10% SDS 
50 µl 10% ammonium persulphate (APS) 
20 µl TEMED 
Final volume = 10ml
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8.3 APPENDIX 2 
 
8.3.1 IC50 calculations from graphs generated from MTT assays in MCF12A 
and MCF7 cells 
 
The average IC50 values of the marine compounds in MCF12A and MCF7 cells were calculated 
using the straight line equations of the trendlines fitted to the three curves generated from the 
results of the MTT assays. Shown below are the calculations of the IC50 values for RUMB-001 in 
MCF12A and MCF7 cells (Figure 24).  
MCF12A MCF7 
y = mx + c 
50 = -0.3267x + 100.19 
x = 153.63 µM 
y = mx + c 
50 = -0.3516x + 85.512 
x = 101.00 µM 
y = mx + c 
50 = -0.2138x + 100.95 
x = 238.31 µM 
The average IC50 of RUMB-001 in MCF12A 
cells is therefore 164.31 µM ± 69.3  
This value is greater than the highest 
compound concentration tested and may be an 
underestimation. Therefore, the IC50 > 164.31 
µM. 
y = mx + c 
50 = -0.9279x + 106.24 
x = 60.61 µM 
y = mx + c 
50 = -0.8371x + 100.78 
x = 60.66 µM 
y = mx + c 
50 = -0.8732x + 96.266 
x = 52.98 µM 
The average IC50 of RUMB-001 in MCF7 cells 
is therefore 58.09 µM ± 4.4 
This approach was used to calculate all of the IC50 values (paclitaxel and the remaining 
compounds) from the dose response curves shown in Figure 25, Figure 26, Figure 27 and Figure 
28. 
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Figure 24: Determination of the IC50 value of RUMB-001 in MCF12A (A) and MCF7 (B) 
cells 
MCF12A (A) and MCF7 (B) cells were treated with between 0.5 µM and 100 µM RUMB-001 for 96 hours 
(triplicates are shown as black, red and blue lines). The IC50 values of RUMB-001 in the different cell lines was 
calculated from the trendlines of the triplicate curves and an average of the triplicate IC50 values was calculated to 
determine the overall average IC50 value of RUMB-001 in each cell line. 
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Figure 25: Determination of the IC50 value of paclitaxel (1), RUMB-001 (2) and RUMB-002 (3) in MCF12A (A) and MCF7 (B) cells. 
1: MCF12A (A) and MCF7 (B) cells were treated with between 0.01 µM and 0.15 µM paclitaxel for 96 hours, 2: MCF12A (A) and MCF7 (B) cells were treated with 
between 0.5 µM and 100 µM RUMB-001 for 96 hours, 3: MCF12A (A) and MCF7 (B) cells were treated with between 0.5 µM and 100 µM RUMB-002 for 96 hours 
(triplicates are shown as green, red and blue lines). The IC50 values of these compounds in the different cell lines was calculated from the trendlines of the triplicate 
curves and an average of the triplicate IC50 values was calculated to determine the overall average IC50 value of the different compounds in each cell line. 
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Figure 26: Determination of the IC50 value of RUMB-003 (1), RUMB-004 (2) and RUMB-005 (3) in MCF12A (A) and MCF7 (B) 
cells. 
1: MCF12A (A) and MCF7 (B) cells were treated with between 0.05 µM and 100 µM RUMB-003 for 96 hours, 2: MCF12A (A) and MCF7 (B) cells were treated with 
between 0.5 µM and 100 µM RUMB-004 for 96 hours, 3: MCF12A (A) and MCF7 (B) cells were treated with between 0.5 µM and 100 µM RUMB-005 for 96 hours 
(triplicates are shown as green, red and blue lines). The IC50 values of these compounds in the different cell lines was calculated from the trendlines of the triplicate 
curves and an average of the triplicate IC50 values was calculated to determine the overall average IC50 value of the different compounds in each cell line. 
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Figure 27: Determination of the IC50 value of RUMB-007 (1), RUMB-008 (2) and RUMB-010 (3) in MCF12A (A) and MCF7 (B) 
cells. 
1: MCF12A (A) and MCF7 (B) cells were treated with between 0.05 µM and 100 µM RUMB-007 for 96 hours, 2: MCF12A (A) and MCF7 (B) cells were treated with 
between 0.5 µM and 100 µM RUMB-008 for 96 hours, 3: MCF12A (A) and MCF7 (B) cells were treated with between 0.5 µM and 100 µM RUMB-010 for 96 hours 
(triplicates are shown as green, red and blue lines). The IC50 values of these compounds in the different cell lines was calculated from the trendlines of the triplicate 
curves and an average of the triplicate IC50 values was calculated to determine the overall average IC50 value of the different compounds in each cell line. 
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Figure 28: Determination of the IC50 value of RUMB-015 (1) and RUMB-017/018 (2) in MCF12A (A) and MCF7 (B) cells. 
1: MCF12A (A) cells were treated with between 0.5 µM and 100 µM RUMB-015 and MCF7 (B) cells were treated with between 0.01 µM and 5 µM RUMB-015 for 96 
hours, 2: MCF12A (A) and MCF7 (B) cells were treated with between 0.5 µM and 100 µM RUMB-017/018 for 96 hours for 96 hours (triplicates are shown as green, 
red and blue lines). The IC50 values of these compounds in the different cell lines was calculated from the trendlines of the triplicate curves and an average of the 
triplicate IC50 values was calculated to determine the overall average IC50 value of the different compounds in each cell line. 
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8.4 APPENDIX 3 
 
Table 7: Concentrations of priority compounds used in treatment of MCF7 cells to 
determine the effect of these compounds on the MCF7 side population 
 
Compound Concentration (µM) 
RUMB-001 80 
RUMB-002 80 
RUMB-007 40 
RUMB-010 80 
RUMB-015 10 
RUMB-017/018 300 
 
 
Figure 29: Comparison of the percentage of ABCG2+ cells present in MCF7 cells after 
treatment with the priority compounds. 
The percentage of ABCG2+ cells present in MCF7 cells (20 000 cells counted) after treatment with 0.25% DMSO, 
10 nM paclitaxel, 80 µM RUMB-001, 80 µM RUMB-002, 40 µM RUMB-007, 80 µM RUMB-010, 10 µM RUMB-
015 and 300 µM RUMB-017/018 for 96 hours and analysed by flow cytometry after staining with an anti-human 
ABCG2 antibody. 
